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Executive Summary 
The research project “From Research to Market: What the EU can learn
from  the  USA”  addresses  the  gap  between  laboratory  research  and
market. I examine how government, universities and private companies
facilitate the transition of research results to market in the USA. I present
various programs that are available to the researchers and entrepreneurs
in the US and invite to consider them for implementation in Europe. 
Specifically, I address the following questions:
 When the research is ready to be commercialized and by whom;
 What are the mechanisms that government, university and industry 
put in place to facilitate a transition of the research results to 
market (the role of technology transfer office, collaboration between
university and industry, support for creation of startups)
 What is the role of finance in bringing the technology to market.
I argue that different stages of lab-to-market transfer require different
mechanisms that should not be limited to funding but include technology
transfer  assistance  and  advice  on  intellectual  property,  mentoring  by
peers  and  industry  mentors  and  access  to  the  laboratory  space  and
incubators.  I  conclude that  the Bay Area answer to closing the lab-to-
market  gap  is  by  a  combination  of  support  mechanisms that
reinforce  and  complement each  other,  when  implemented
simultaneously.  I  invite  to  discuss  which  of  the  US  initiatives  and
programs described in  this  report  shall  be promoted in  Europe and at
which level.
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 “Learn all you can from the entrepreneurs of Silicon Valley 
but don’t become like them. “ 
Vivek Wadhwa
Introduction
The present study addresses the crucial area where Europe, despite
its efforts, does not have the leading position in the world: the effective
transition of the research results to market, leading to creation of new
companies,  jobs  and economic  growth.  My interest  in  the  subject  was
provoked by the report of Pascal Lamy, the chair of the independent High
Level  Group  on  maximizing  the  impact  of  EU  Research  &  Innovation
Program who noted that Europe is good at growing science, “but not good
enough at getting growth out of science."1 This report was one of building
blocks  of  the  new  Horizon  EU  program  2021-2027  that  commits  to
investing  in  excellent  science  in  Europe  and  strengthening  the  EU's
industrial  innovation  by  means  of  investments  in  key  technologies,
greater access to capital, and support for small businesses. The program
also  intends  to  promote  breakthrough  innovations  through  the
establishment of the European Innovation Council.  
The importance of transition of the research results to market was
recognized  in  the  US  decades  ago.  The  “Lab-to-Market”  initiative  by
Barack Obama was announced in 2011. Its goal was set to accelerate and
improve  the  transfer  of  new  technologies  from  lab  to  market.  The
initiative included optimization of federal patent management , increase
in  use  of  federally  funded  research  by  innovators,  enhancing
entrepreneurial  education,  maximizing  the  impact  of  SBIR  and  STTR
programs.2 The  proposed  measures  included  creation  of  business
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incubators and technology transfer centers in the universities, creation of
federal agency/industry partnerships assisting the startup companies and
provision  of  entrepreneurship  training  to  the  scientists  and  engineers.
These objectives were carried forward in Trump management agenda of
2018.3
A number of the US Federal and private initiatives were successfully
put in place aiming to close the “valley of death”4. In this report I explore
some of them. I group them into government, universities and industry
initiatives designed to  facilitate the  transition of research results to the
market. I aim to answer the following questions:
 When is it the right time to commercialize the research and by 
whom;
 What are the mechanisms that government, university and industry 
put in place to facilitate a transition of research results to market 
(the role of technology transfer office, collaboration between 
university and industry, support for creation of startups)
 What is the role of finance in bringing the technology to market.
Methodology
The starting point of the study was the moment when the innovation
had  been  created  as  a  result  of  the  research  done  within  a  research
center of the university, institute or a private company. The end point of
the study was the commercialization of the product. The place of study
was California, the United States. 
I  focus  is  on  a  deep  tech,  defined  broadly  as  cutting-edge
technologies that are built on tangible scientific discoveries or meaningful
engineering innovations that are intended to solve complex problems that
affect  the  real  world.   These  technologies  are  the  riskiest,  the  most
investment  intensive  and  need  considerable  time  and  money  to  be
shaped into a commercial product. At the same time, such breakthrough
innovations can drastically change the course of the human’s history. 
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I  carried  out  a  qualitative  research  including  a  review  of  the
literature  on  the  subject,  a  review  of  publicly  available  information,
complemented with over 40 semi-structured eye-to-eye interviews with
researchers,  faculty,  venture  capitalists,  angel  investors,  startups  and
entrepreneurs  (I  met  with  several  interviewees  more  than  once).
Interviewees  were  chosen  based  on  the  interviewees  current  or  past
positions within organizations and their previous expertise in technology
transfer and commercialization of technology. The goals of the interviews
were:  to  understand  the  role  that  the  actors  play  in  lab  to  market
transition; to gather examples of current initiatives in place that function
well  but also those in need of the improvements;  to discuss the pilots
those efficiency remains to be assessed; to validate the information from
the  research  literature  and  other  sources.  The  interviews  were
complemented with the visits to the laboratories and technology centers
of  Autodesk,  Lawrence  Berkeley  National  Laboratory,  Neuroscape
(laboratory  of  the  Neurosciences  institute  of  UCSF)  and Virtual  Human
Interaction  Lab (Stanford  University).  For  logistical  reasons  the  face to
face interviews were conducted in the Bay area – Berkeley, San Francisco
and Silicon Valley. The interviews in other areas of California were carried
out by phone. The detailed list of actors that were interviewed is enclosed
in Annex 1.
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Figure 1. Actors interviewed for the study 
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My  participation  in  three  innovation  courses  at  Haas  Business
School,  Berkeley  Law  School  and Sutardja  Center  for  Technology  and
Entrepreneurship  at  UC  Berkeley  complemented  my  knowledge  of  the
technology transfer process from the laboratory to market.
1. From University Lab to Market 
Imagine a scenario when a new technology has been created in the
laboratory.5 This process most probably included numerous experiments
and failed attempts. The innovation could have been created by mistake
or  error,  the  situation  that  is  not  uncommon6 and that  underlines  the
importance of  experimentation.  Not always the positive results are the
only valuable results in science.7 So the technology is there, however in its
very early stage. More tests and data collection should be carried out to
prove the technology is working as intended, perhaps a working prototype
needs to be built. It still may not be clear how exactly the technology can
be used and who would buy it. But this is the start of the story. 
Figure 2: The standard process
of technology transfer8
1.1.  From Idea  to
Invention Disclosure 
During  the process  of  lab  to
market  transfer, there  are  a  few
critical decisions, that need to be taken by a researcher (being a principal
investigator (PI), the head of laboratory, a postdoc or a PhD student.) The
first one is when (and if at all) to take the research out of the university
laboratory  to  market.  The  first  step  in  the  process  is  an  invention’s
disclosure to the technology transfer office (TTO). It is a starting point for
consideration  of  the  patentability.  At  the  moment  of  the  invention
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disclosure  it  might  not  be  clear  if  the  technology  in  question  has  a
potential  to  be  commercialized.  It  normally  would  be  very  early  stage
technology  but  the  researcher  shall  contact  the  licensing  officers  very
early, still at the pre-disclosure stage, so the correct procedure is followed
since the beginning.
Can  the  technology  be  transferred  to  market  without  the  invention
disclosure?  It  is  unlikely  and  irregular.  All  intellectual  property  (IP)  on
inventions  produced  in  the  US  university  laboratories  belong  to  the
university and thus shall  be licensed. Bringing technology to the world
without  taking legal  arrangements infringes the rights of  the university
and can result in penal proceedings.
Next decision is when it is the right moment for a scientific publication.
The reputation and promotion opportunities for the researcher are linked
to the number of publications,  name of the journals  where articles are
published and number of citations they trigger. The wish to publish the
discovery as quickly  as possible  is  quite  understandable:  the desire  to
share the invention with the peer researchers, to receive a feedback and
open  a  discussion  on  the  further  steps  of  the  research,  a  wish  for
recognition, all these considerations can push the scientist to publish the
discovery as quickly as possible. However, if one intends to commercialize
the technology, other considerations would come into play. Protection of
intellectual property is one of them. In the US, inventors have one year
from the date of publication to file a patent. However, in other countries
(also the EU), the patent rights are lost at the moment of publication and
thus alignment between the filing for the patent and the publication is of
paramount importance. The delayed publication may also postpone the
imitation of  the technology by rivals,  a valid argument in the business
world.
Following the invention disclosure, the TTO carries out the preliminary
assessment  aimed  to  estimate  if  there  is  a  market  interest  for  the
invention. The possibility of patent application is considered, keeping in
mind that the technology should meet certain criteria to be patentable: to
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be new, useful, patent eligible and non-obvious.9 As patent costs are quite
high (about USD 50,000) the TTO can decide against the patenting if no
demand for licensing technology is foreseen. In the US it is possible to file
for provisional patent, that gives the founder 12-18 months grace period
to determine the possibilities of licensing of the technology and to decide
on whether to pursue final patent application.10
1.2.  To Patent or Not to Patent 
US Department of Energy (DoE) takes a broad view on the technology
transfer  stating  that  “Technology  transfer  can  mean  many  things  –
technical assistance to solve a specific problem, use of unique facilities,
licensing of patents and software, exchange of personnel, and cooperative
research agreements  while  ensuring fairness  of  opportunity,  protecting
the national security, promoting the economic interests of the nation, and
preventing inappropriate competition with the private sector.”11 Often, the
term “technology  transfer”   relates  to  the  legal  transfer  of  innovative
solutions  of  problems that are protected by intellectual  property rights
from  one  party  to  another.  When  the  technology  is  created  in  the
university  or  research  laboratory  and  is  being  prepared  to  enter  the
market, the formalized legal agreement “releasing” the technology from
the laboratory must be concluded. 
The  critical  legislative  act  for  understanding  industry-university
relationship in the US is the Bayh-Dole Act or Patent and Trademark Law
Amendments  Act  of  1980.  It  deals  with  intellectual  property  arising
from federal government-funded research. The key change introduced by
Bayh–Dole Act is in ownership of inventions made with federal funding.
Before the Bayh–Dole Act, federal research funding contracts and grants
obligated  inventors  (wherever  they  worked)  to  assign  inventions  they
made  using  federal  funding  to  the  federal  government. Bayh–Dole
permitted a university, small business, or non-profit institution to pursue
ownership of an invention in preference to the government.12 
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In  the US,  the intellectual  property (IP)  produced in  the university’s
laboratory  is  the  propriety  of  the  university.13 The  universities  secure
intellectual  property  rights  and then license those rights  to  companies
who  develop  the  commercially  available  products  and  services.  A
company  may  already  exist  or  be  created  for  the  purposes  of
commercialization  of  the  technology.  Universities  cannot  directly
commercialize the research discoveries.14
Risky  R&D  process  including  the  manufacturing  and  regulatory
approvals  to  bring  early  stage  discoveries  to  the  point  of  practical
application  cost  money.  Without  the  protection  afforded  by the patent
license, the industry would not risk their funds and resources on lengthy
R&D programs  that  are  necessary  to  commercialize  products.15 The IP
licensing gives industry an incentive to invest. It is particularly true in case
of  deep  technologies,  like  life  sciences  for  example.16 The  timeline  to
successfully develop a commercial product from an academic discovery
can vary widely, but it most often takes 3-10 years. Importantly, in case of
a  breakthrough  technology,  like  gene  editing  for  example,  the
commercialization  process  can  take  well  over  10  years  and  can  cost
several  billion  dollars.  In  contrast  in  software  development,  where  the
technological advancements are extremely quick and versatile, it is often
viewed that time and money spent on filing the patent could be better
spent on development of the technology. 
The US had first-to-invent system until 2013, when it turned to the first-
to-file system to be in alignment with the rest of the world.17 In a first-to-
file system, the right to grant a patent for a given invention lies with the
first person to file a patent application regardless of the date of invention. 
Having a patent does not guarantee a care-free ride. According to the
startup CellFe18, that has developed novel cell delivery technology, that is
patented but which principle is quite simple to imitate, there are many
ways to “go around” the patent  that  competitors  may use.  In  case of
infringement of the patent, the cost of proving this infringement is so high
that it may not be feasible for a small company to engage in the lengthy
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and  costly  legal  proceedings.  (Patenting  may  still  be  wise  to  protect
oneself against others claiming property of their own developments.)
If  the inventor does not intend to generate IP in the university,  she
needs to clearly distinguish her invention from the university work that
s/he is doing. This is what happened to the biotech startup Visolis19, who
from the beginning worked on the technology outside the university, in
the privately rented wet laboratory.
1.3.  Who and When is Bringing the Technology to Market?
At the different stages of the technological development two types of
risks  have  to  be  addressed.  One  is  the  invention  risk,  answering  the
question  whether  technology  can  actually  work  and  if  it  is  sufficiently
mature and robust. Another one is the customer/market risk, establishing
if  the  technology  would  have  the  customers  and  the  market.20 The
decision to take the technology out of the university laboratory should be
done with consideration of both risks. 
From one side, the longer the technology stays in the university, the
costlier licensing would be. From another side, gathering more data and
working on the technology by using the resources of the university allows
bringing the technology to market in a more mature stage. It is up to the
inventor to decide when to commercialize (license) the technology.21 So
who  would  bring  the  technology  from the  university  laboratory  to  the
market?  
Would it be a principal investigator? Being an expert in technology,
he is deeply rooted in the academic system and is unlikely to exchange
the security of his position for an unstable and risky startup business. But
she could be an adviser to the company, letting others “to do the hard
work” of launching the new company. The PI, through her connections in
academia and industry may promote the technology during conferences
and networking events. She could raise interest of a large company who
would be ready to license the technology or cooperate via a joint research
project  to  develop  it  further  in  the  university  setting.  The  interesting
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approach to engage the PI in the commercialization of the technology is
taken by the i-CORPS program of the National Science Foundation (NSF)
(more in section 2.3). 
Would it be a  postdoc/junior researcher? In the US, the big hopes
are put on the young scientists to bring the technology to market. Their
jobs in laboratories are temporary and according to the statistics, only 5%
of them will  be able to continue their careers in academia. One of the
opportunities  that  is  open  to  them is  to  found  a  startup.  Universities
increasingly  support  researchers  in  this  role  by  providing  courses,
seminars and mentoring on what it takes to become an entrepreneur, so
everyone  could  assess  whether  this  path  would  suit  them.  (more  in
section 3.6.)
In  order  to achieve the highest benefits  for  the society and also to
ensure the flow of revenue to the university, it is in the interest of the
university  to license the technology to the party that is  best suited to
create the  product  on  the  basis  of  the  technology  and bring  it  to  the
market in a quick and efficient way. In some cases, the TTO shall make a
choice  between  licensing  to  an  existing  company  (well  established
industry)  or  to  a  newly  created  start-up,  formed  by  the
researcher/inventor of the technology. The TTO shall remain impartial and
think  of  the  best  possible  return  from  the  commercialization  of  the
technology. However, naturally, it gives a consideration to the inventor of
the  technology  that  may  have  the  in-depth  knowledge  and  unparallel
motivation to bring the technology to the market. 
Licensing to  the  inventor  is  not  unproblematic.22 The inventor  must
incorporate the company, and then have an initial funding to be able to
pay for  the licensing fee.23 Statistics  showing that 90% of  startups fail
increases the risks of licensing to a newly founded startup. The TTO of UC
Berkeley attempts to address this risk by granting non-exclusive licensing
rights, which means that the technology can be licensed to a few parties
at  the  same  time.  According  to  Mike  Cohen,  Director  of  TTO  of  UC
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Berkeley,  startups are more efficient (and quick)  to develop and put a
product to the market.24 
Sometimes  an  experienced  industry  partner  can  commercialize  the
technology better and turn it more efficiently into a new product, leaving
the inventor with the royalties from the licensing and freedom to pursue
the next research. An established company may have readily available
financial  and  human  resources,  as  well  as  technical  equipment,  in
advantage over the newly founded company.  On a flip side, licensing to
an existing company could mean losing the control of the technology and
potential delay in bringing it forward to the market. An existing company
may  put  the  licensed  technology  “on  hold”  due  to  other  priorities.  If
technology would create a competition to their already launched products,
it could even prevent its launch to the market.
Often existing companies are not willing to take over very early stage
technologies and invest into technology development. They wait that the
technology  “de-risks”  itself,  perhaps  following  the  creation  and
development of a startup and, at a later stage, consider its acquisition. 
While UC Berkeley tends to grant a non-exclusive licensing25, as not to
forgo the opportunity if the technology would create significant returns,
LBL  approach  is  different.  By  engaging  in  the  cooperative  research
agreements  (industry  financially  contributes  in  return  to  research  on
specifically defined problem), LBL grants exclusive license to the industry
willing to commercialize the technology. These decisions are done by the
Technology Transfer Office (TTO) that play an important role in bringing
technologies  to  market.  The TTOs have different  missions,  governance
structures and sources of financing at different universities:26
 Facilitate the technology transfer from university to market.
 Support  and  foster  entrepreneurial  efforts  of  the  inventors  to
enhance their capacity to bring their invention to market. 
 Seek to maximize the financial returns on intellectual properties to
help fund the university. 
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 Raise money and support new inventors by bringing in successful
entrepreneurs back to the University’s community.27
One of the roles is to advertise the technology available for licensing.
The TTOs of UCSF, UC Berkeley, Lawrence Berkeley National Laboratory
(LBL),  Caltech  and  Federal  Laboratories  have  the  databases  of  the
technologies ready to be licensed that are open for consultation. However,
such passive offering of the technology does not help much technology
commercialization. The industry is not interested to absorb technologies in
early stage  and with no clear application to a product. According to the
Chief TTO of LBL, Dr. Elsie Quaite-Randall, “push marketing does not work
– creation of patent databases, “advertising” of the research by the TTO is
not  effective”.28 According to her,  there are two approaches that have
proven to be successful: one is the focused programmes, conferences and
symposia  where  people  meet  each  other  and  establish  personal
connections  that  can  result  in  collaborative  research.  And  another
approach  tested  by  LBL  in  collaboration  with  other  US  national
laboratories  -  a  multipatent  portfolio  approach adopted  by  the
National  Laboratories  in  the  US.  The  reason  to  create  a  multipatent
portfolio  was  driven  by  the  fact  that  the  industry  is  not  interested  to
approach the national laboratories for just one or two patents. In order to
maximize  the  interest  from  the  existing  companies,  six  national  US
laboratories  funded by the  Department  of  Energy  (DOE)  screened and
constructed multipatent portfolios that are tailored for the industry needs.
The common database of patents was created, analyzed and patents were
clustered  by  subject  by  the  technology  experts,  in  order  to  build  the
critical  mass. The interinstitutional agreement between the laboratories
was  concluded  (as  the  fact  that  patents  were  owned  by  different
laboratories had to be addressed). Then, the portfolios were presented to
the industry at show case events.
Lessons  learned:  Following  the  successful  adoption  of  the
multipatent  portfolio  by  the  National  Laboratories,  this  new
approach  considered  to  be  a  success  in  bringing  laboratories
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research to industry (it even won an institutional award). Similar
practice is also taken on board by the University of California,
that has recently launched an initiative to map, bundle, evaluate
and revive all of university’s IP and patents, in order to better
commercialize  them and  to  better  serve  industry  interest  and
needs.(each  of  University  of  California  campuses  has  its  own
Technology Transfer Office).29 
1.4.  The  Assessment  of  Technological  Potential  and
Company Viability 
Having a promising technology and excellent team is important, but
money is essential in bringing technology to market. An ideal investment
approach would be the gradual one-source support that links solutions at
the earliest stages of development to more mature solutions. However, in
the  real  world,  technology  commercialization  has  to  be  supported  by
various  independent  investors  and  partners,  each  contributing  at  a
different stage of technology life cycle. 
Investors typically look into the idea, the team, the product and its fit
to the market, the growing rate of customer adoption, and potential of
revenues. Depending on the team and founder’s reputation, it is possible
to raise money without the customer/revenue traction, but it is unlikely.
Two main factors: the team and the market are cited as the critical factors
in evaluation of the startups’ potential and investment decision.
In  analogy with the Technology Readiness  level  (TRL)  developed by
NASA,  Steve  Blank  introduced  the  Investment  Readiness  Level  (IRL),
demonstrating  what  it  takes  for  a  company to  get  financing.  The  tool
helps to assess the chances of raising a round of financing of a startup at
its current stage of development.
While the TRLs and IRLs are necessary for testing demand for a certain
technology solution they lacks the integration of a social dimension that is
often the case with shared infrastructure.30 The market readiness is an
important indicator in order to establish whether the markets are ready to
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accept  the  technology.  The  community  readiness  level  (CRL)  scale
addresses the readiness of the markets. 
Figure 3. Technology, Investment and Community readiness levels
combined serve as a canvas for assessing the chances of the technology
to be adopted by the market
There  is  a  quasi-unified  approach  on  evaluating  the  promising
technology and assessment of company’s viability in the Silicon Valley.
Internal  Google  Accelerator  Area  120  boils  it  down  to  three  key
components: the team, with the focus on team diversity, the problem or
need the technology tries to solve, and the impact  it would make if the
problem is solved. (for more details, see item 5.2).
ARPA-E project teams are asked to prepare a Tech-to-Market Plan,
which  serves  to  guide  planned  activities  to  assess  and  advance  the
commercial viability of their technology. The successful projects needs to
demonstrate a transformational technical concept or prototype. Two areas
that are considered in assessing the viability of a technology and potential
for impact are: 
o Market: Will  a product based on the technology create enough
economic value to drive adoption by the market? 
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o Manufacturing: Can  a  product  based  on  the  technology  be
manufactured cost effectively and at reasonable scale? 
Three additional factors are taken into account in evaluating a project’s
long-term success:
o Team: Does the team have the right skills and capabilities? 
o Intellectual Property: What is the plan for securing intellectual
property related to the technology? 
o Funding: If the project is a success, how will the effort be funded
after ARPA-E’s involvement? 31
Typical startup evaluation by a Venture Capital firm focuses on the
five  components:  a  clear  high  value  market  with  advantageous
positioning,  product  that meets customer needs and a clear indication
that  customers  are willing  to  pay for  it,  a  competitive  advantage that
customers value and the team can execute on, a highly skilled team in
the areas that are critical to success, a company structure that allows VC
funding and exit in a 10-year timeline”32
Team is at the core of the funding decision.  Other three questions
are asked when assessing a deep tech company: Why now? Is this feasible
in a venture time frame? How do you build  a business in that time? 33
More developed evaluation  matrix  shows other  questions  that  the VCs
consider when evaluating the company’s potential to scale:
Criteria Questions
Value 
Proposition
What is the addressed problem? How does the 
solution satisfy the unmet need? Who values that? 
Cost/benefit ratio?
Product What does product offer? How does it affect clinical 
decision making? How does it fit into clinician 
workflow? Does it replace any product?
Technology What is the underlying science and engineering? 
17
Alternatives? What does the proof of principle study 
shows? Publications? Validation? Development plan?
Competition Current and emergent players profiles
Market Target market segments? Market size model with 
unit volume, penetration curve, pricing
Regulatory path FDA or EMA routes? Data submission requirement? 
Pre-IND FDA feedback?
Business model Revenue source? Product economics? Pricing 
strategy? Out licensing? Partnering?
IP Barrier to competition. Patent filings? Breadth and 
strength of claims? Prosecution status? Patent 
analysis? Freedom to operate? License terms? 
Management Team background? Advisory board? Staffing plan? 
Organization structure?
Financing Cash requirements VC key milestones? Sources of 
capital? Use of funds? Future capital requirements?
Reimbursement How do you get paid?
Exit Exit path? At what stage? Potential acquirers? ROI? 
Comparables?
Figure 4. Sample Checklist of a VC company evaluating life
science/biotech startup 
1.5.  Lab-to-market Example: Neuroracer’s Video Game
Neuroscape center, a translational neoroscience laboratory, is a part of
UC San Francisco (medical graduate school). It houses about 100 principal
investigators and more than 500 researchers and staff.  The Neuroscape
center emerged from Dr. Adam Gazzaley’s lab, founded at UCSF campus
in July 2005. Dr. Gazzaley’s research aims to deliver a therapy for people
struggling  with  memory  problems,  for  example,  or  ADHD.  Gazzaley
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believes  games  he's  developing  could  become  "the  world's  first  FDA-
approved prescribed video game”.
The  laboratory  deals  with  the  research  until  the  proof  of  concept
stage34. All of the computer games developed at Neuroscape are research
tools, not commercially available products. Neuroscape builds prototypes
that are tested through scientific experiments to determine their effect on
cognitive abilities. This is only the first step to creating a validated product
for general use. There are several running projects, at the moment, at
different stages of development.
Building a product  based on a prototype is  an expensive and time-
consuming endeavor. Neuroscape, as an academic center, has neither the
resources nor the objective to build and support commercial games. If the
results of the studies show that the game may improve patients’ cognitive
abilities, then it may be licensed through UCSF to a company that is able
to develop it into a viable product. 
In early 2009, Dr. Gazzaley, the head of Neuroscape center, saw such
an  opportunity  to  move  beyond  the  lab’s  focus  on  basic  science  by
applying the gaming technique to the aging brain to improve functioning
in  individuals  and  developed  a  therapeutic  video  game  (Neuroracer)
designed  to  improve  cognition  in  older  adults.  This  technology
development project and the series of research studies that followed it,
over the next 4 years, resulted in a 2013 publication in the journal Nature,
a  UCSF  patent  filing  of  the  methodology  behind  the  game  training
approach,  and  the  founding  of  a  novel  healthcare  company  — Akili
Interactive  Labs —  to  transform  this  breakthrough   into  commercial
product and advance the game as a clinical therapeutic device. 
So  far,  only  one  game  from  the  center  has  been  licenced  under
exclusive  licence  and  is  evolving  into  a  commercial  product  and  it  is
Neuroracer.  All  the  other  games  are  still  being  tested  in
ongoing studies. Akili  Interactive Labs is developing a clinical  product in
the form of a mobile video game (“Project:  EVO”) that is based on the
technology  behind  Neuroracer.  In  2018,   Akili  added  an  extra  $13
million to a prior $55 million Series C round, bringing the company’s total
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funding  to  just  over  $140 million.  The FDA is  currently  reviewing  Akili
Interactive  Labs’  first  experimental  product—a  mobile  video  game
designed  to  assess  and  treat  attention  deficit  hyperactivity  disorder
(ADHD)—after  Boston-based  Akili reported  a  successful  348-patient
clinical  trial  last  December.  After  the  FDA  approval,  the  game  may
become available to the general public. 
2. Governmental Measures Facilitating the Transition of 
Research Results to Market
In  the  Silicon  Valley,  on  the  wake  of  computers  industry,  federal
government has acted in three capacities: “as setter of the rules by which
firms operate”, “as buyer of their products” and “as financier of research
and  early  system  development”.35 Now,  government  initiatives  are
particularly  important  in  supporting  the  very  early  commercialization
attempts when technology is not of interest to any private investor. It is
still  immature,  prototype  not  yet  created  and  tested,  let  alone  the
absence of potential traction in the form of revenue or customers. The
support at this stage is available through the “traditional” federal grant
program  of  SBIR  (The  Small  Business  Innovation  Research).  This  is  a
highly competitive program that encourages domestic small businesses to
engage in federal research that has the potential for commercialization.
Another  program is  STTR (Small  Business  Technology Transfer),  whose
goal is to facilitate the transfer of technology developed by a research
institution  through  entrepreneurship.  The  above  programs  are  highly
regarded by the researchers,  although the success rate for  first  phase
grant is about 12-15%. This award rate increases for the second phase
grants up to 20% (see chapter 6.1.). 
The  Advanced  Research  Projects  Agency (ARPA-E) within  the  U.S.
Department of Energy (DOE) was modeled after the successful Defense
Advanced Research Projects Agency (DARPA) and created to address the
lab to market gap.36 Preparing technologies for an eventual transfer from
lab to market is a key element of ARPA-E's mission. It focuses on “high
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risk,  high reward” technologies that isn’t being pursued anywhere else.
The top talents are recruited on a temporary contract basis that ensures
fluidity  between  industry  and  Agency.  The  hands-on  and  autonomous
approach means program directors are involved in developing budgets,
timelines and milestones that projects must meet to receive continued
funding.  This  metric-driven process also means that  when projects  are
underperforming and need to be terminated, these decisions can be made
swiftly. 
Other government funded programs in the US that support transition
of research results to the market are the following: 
 Fellowships  to  the  scientists  that  bring  technology  closer  to  the
market;
 Shared User Facility - use (rent) of facilities, specialized equipment
or testing centers;
 I-CorpsTm program to help the customer discovery process for new
entrepreneurs;
 Researchers exchange and Entrepreneur-in-Residence programs.
2.1.  Fellowship  to  Support  Entrepreneurial  Scientists
(example of Cyclotron Road) 
Cyclotron Road program was created in 2014 at the Lawrence Berkeley
National  Lab  and  is  funded  by  the  Department  of  Energy  Advanced
Manufacturing  Office.  It  aims  to  “create  a  new  institutional  home  for
application-driven research”37 in the sectors of energy, water, food, and
health and to provide support to mature ideas into commercially viable
products. 
The former DARPA director Arati Prabhakar commented: “The Cyclotron
Road model recognizes that there are really smart people with a lot of
passion to deeply understand research advances. But in the way they’ve
been trained, there is no reason to expect they have the moves to go
commercialize that technology, or know what the best commercialization
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path might be. So, bringing them in and giving them access to laboratory
facilities they need to do their work, and also immersing them in thinking
about  business — this  is  very  different  from  just  thinking  about  the
research or the science.”38
The program focuses solely on hard technology. It provides two years
funding  that  includes  salary,  health  insurance,  travel  and  research
expenses,  provides  laboratories  for  use.  It  is  a  grant  in  its  essence.
According to Brenna Tiegler, a Head of Program Operations at Cyclotron
Road, the unique feature of Cyclotron road is that the researcher keeps
the IP rights (despite working in the federally funded lab). The program
accepts  projects  at  the  very  early  stage.  It  is  worth  to  mention  that
Cyclotron Road enjoys exceptional access to the expertise and knowledge
both of UC Berkeley and Lawrence Berkeley National Laboratory. 
Since 2014,  four  cohorts  of  fellows had graduated.  The teams have
crossed the science-to-product bridge, having either developed their first
prototype  or  acquired  sufficient  funding  to  do  so.  By  advancing  their
research to the stage of the prototype, allowed the teams the access to a
variety  of  private  sources  –  angel  investors,  venture  capitalists,
philanthropists, and industry-backed strategic investors. 
Figure 5. Extract from Cyclotron Road impact report39
Lesson  learned:  The  value  added  of  this  program  is  the
collaborative environment with the very clear mission to advance
a technology into the commercial product, so all efforts during
the two years programme are devoted to achieving this goal.  
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2.2.  Shared  User  Facility  and  Small  Vouchers Program
(example of Molecular Foundry)
Shared user  facility,  funded by the Department  of  Energy,  provides
users  with  access  to  cutting-edge  expertise  and  instrumentation  in
nanosciences. The access is open to researchers from the universities and
companies  (small  businesses  are  particularly  encouraged)  providing
materials  and facilities  that  are not  available  everywhere.  In  2018,  45
researchers were working in this facility on their research while helping
the external users of the foundry with advice and assistance. 
Brandon Brough, Deputy Director, notes that 95% of all users are small
businesses. Besides regular bi-annual admissions, a rapid access program
also exists. Access is based only on a two-page proposal and is completely
free  for  one  year,  both  for  the  use  of  laboratories  and  scientist’s
assistance and support.
There are two important points that characterizes the program. Firstly,
it is the fact that IP is owned by the inventor. (If one makes a discovery in
cooperation with scientists from Molecular Foundry then the IP should be
shared).
Secondly,  the Foundry’s  primary focus is  the facilitation of  the non-
proprietary research whose purpose is the publication and not scaling up
the business. Thus, the companies shall present their ideas as a research
concepts. It does not prevent them, however, from using the developed
technology for their business purposes. 
The described two programs: Cyclotron Road and Molecular Foundry
are focused on the development of the technology at the very early stage,
before prototype creation. Both allow the researcher to keep the IP rights. 
Another program of the Department of Energy that is at its pilot stage:
“Small  Business  Vouchers  (SBV)  program” aims  to  provide  small
businesses  access  to  selected  national  labs—making  the  contracting
process simple, lab practices transparent, and access to the labs’ unique
facilities practical. Through SBV, selected small businesses in the field of
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clean energy, receive access to the state-of-the-art facilities and experts
at participating DOE national labs, while the labs expand their knowledge
of, and involvement with, the private sector, helping small businesses with
advanced  technologies  to  contribute  to  the  US  competitiveness  and
economic growth.40
The above programmes focus on the development and fine tune of the
technology  for  commercialization,  helping  to  address  and  mitigate  the
invention risk. 
Lesson learned:  Provide access to the facilities to experiment
and test new technologies, not only to university students and
federal researchers, but also to startups and anyone interested
to test and experiment with the new technology.
2.3.  National Science Foundation (NSF) Innovation Corps (I-
Corps™)
The I-Corps™ program was created by the National Science Foundation
(NSF) in 2011 to help bringing the academic research it previously funded
to  the  market.  Its  objective  is  to  prepare  scientists  and  engineers  to
extend their focus beyond the university laboratory, and to accelerate the
economic  and  societal  benefits  of  NSF-funded,  basic-research  projects
that are ready to move toward commercialization.  The program aims to
reach a large number of the faculty and scientists via the seven regional
Hubs across the US. The ambition is to setup an innovation ecosystem
within  universities that will  train the next generation of  entrepreneurs,
encourage  partnerships  between  academia  and  industry,  and  boost
commercialization  of  science and technology.  It  is  based on a  special,
accelerated version of Stanford University’s Lean LaunchPad course. Lean
Launchpad  methodology,  based  on  the  work  of  Steve  Blank,  is  the
reference  methodology  in  the  Bay  area  for  commercialization  of
technology.41 The approach engages  the researcher to get out from the
laboratory to the market space and to push her to understand the market
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needs and potential for a new product by interviewing a large number of
potential customers. 
The University of California, Berkeley, UC San Francisco and Stanford
University are forming the “NSF Bay Area Regional  I-Corps Node”.  The
best graduates of regional nodes enter the national competition where the
cohort of 24 teams work on their project and present their results to the
panel, who decides on the winning team. The team receives about 55,000
USD to cover travel and related expenses. The teams are composed of
three  members:  the  technical  lead,  the  entrepreneurial  lead  and  the
mentor.  By  adding  the  mentor  from  the  industry  to  the  team,  the
connection to the industry is ensured. The technology which potential the
team explores is typically (very) early stage. 
According to Todd Morill, Director of NSF i-CORPS Bay Area Node, the
“hidden agenda” of NSF is that it wants all US professors to go through
the  program  so  later  they  can  pass  the  knowledge  to  their  students
(creation  of  spill  off knowledge  transfer).  The  main  incentive  for  the
professors to participate (and to allow their postdocs to participate) in the
program  is  the  following  message:  “How  many  of  your  students  will
become professors?  The answer is  “probably  zero”.  Do you want your
students to find their place in the industry? The answer is “Yes”. So i-
CORPS will teach you how to help them.”1 In evaluating the results of the
program, Todd Morill mentions the importance of the “negative statistics”.
According to his experience, half of the teams result in deciding on not
forming a company. Is it  a failure? Not really.  It  only means that they
managed to  do a  weighted decision  based on tangible  data that  they
gathered  and  analyzed  to  “succeed  in  not  proceeding” that  saves
them the time and the resources. “If you are destined to fail, then it is
better to fail quicker”.2
The  success  of  NSF  program  led  to  its  adoption  by  other  federal
agencies:  the  Department  of  Energy,  the  Department  of  Defense,  the
12
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National Institute of Health (NIH).  The NIH made it mandatory for the SBIR
holders to participate in the program. 
Lessons learned:  The objective of the program is “to cultivate a
pipeline of university-based researchers who can turn ideas into
successful commercial products”. Multiple federal agencies have
successfully  adopted  a  curriculum  and  one  of  them  made  the
attendance the prerequisite for receiving a federal grant (SBIR). 
2.4.  Science/Industry Exchange programs 
Another  mechanism  of  knowledge  transfer  between  federal
laboratories, universities and industry are through exchange programs:  
 Cooperative  Research  &  Development  Agreements
(CRADAs): Joint  research  between  federal  laboratories  and  the
private sector. The non-Federal party could be an individual from a
state or local government, public or private foundation, university,
company, or non-profit organization, any of which could also be the
licensee of a government-owned invention.
 Entrepreneurial  Leave  Programs: allowing  staff to  take
“entrepreneurial leave,” spending time focused on commercializing
a technology developed in the laboratory. With current examples
at the Department of Energy (DOE) and the Department of Defense
(DOD),  this  type  of  personnel  exchange  is  also  called  an
“Entrepreneurial Separation to Transfer Technology”.
 Entrepreneur-in-Residence  (EIR)  Programs: Entrepreneurs
from outside of government who wish to apply their skills for the
benefit of the public good can do so through EIR programs. EIRs
are  typically  mid-  to  senior-level  professionals  and  may  be
academics,  technology  entrepreneurs,  software  designers,
policymakers,  business  experts,  or  non-profit  leaders  who  have
demonstrated  a  significant  record  of  innovative  achievement  in
their field. 
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Lessons learned: The exchange between academia, industry and
government  allows for  a  circulation  of  best  practices  and the
ideas.  It  unlocks  staff potential  by  forcing  them  to  adapt  to
different cultures and environments that enhance the vision and
perspective  on  the  processes,  preventing  people  from  being
“locked” in their roles and helps extend the borders of science
and  enrich  experiences  of  both  the  participants  and  host
organization. 
3. University-Funded Programs and Initiatives Supporting 
Transition of the Research Results to Market
Universities play a crucial role in research to market transfer. Firstly,
researchers ensure the production of the critical mass of basic and applied
research  leading  to  the  development  of  prospective  technologies  and
products. Secondly, universities concentrate the  young talents that in a
few years’ time will enter the national work force.
The programs on campus help students with the scientific background
to  understand the  basic  business  concepts  as  well  as  learn  about  the
career  opportunities  outside  academia.  They  range  from  information
seminars explaining what it takes to bring the technology to market to
more  concrete  programs  like  i-Corps  that  helps  to  identify  the
market/customers  fit  for  the  given  technology.  The  programs  in  the
accelerators strengthen the business model with the help of the industry
mentors. The overall objective is to:
 Develop instinct in the scientists to identify the technology that has
potential to go to the market;
 Develop the ability to perform market fit analysis to see whether the
markets exist;
 Have  a  network  to  get  in  touch  with  a  group  of  similar  minded
individuals who would help with the advice/direction and guidance –
mentors.
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(A discussion takes place in the US on the role of  the professors in
promoting entrepreneurship. It is argued that there should be distinctive
careers  for  the professors  who conduct  research,  who teach,  and who
promote  entrepreneurship  and  technology  to  market.  Currently,
academia’s award system put more emphasis on the research work of the
faculty, leaving teaching, entrepreneurship and mentoring less rewarded).
In the recent years major universities in the Bay Area have created the
“innovation centers” or “innovation hubs” to concentrate and disseminate
the know-how of research to market process (TTO may be a part of these
centers).  Besides these centralized efforts,  coming from the top of  the
hierarchy, there are many decentralized and independent initiatives and
programs created by the faculties of engineering, business, law and also
other faculties, aimed to support the innovation. 
UC Berkeley is an excellent example of how the innovation ecosystem
has flourished in the last 5 years. With the coordinated efforts coming
from the University of California headquarters and the specific initiatives
launched  by  the  different  departments,  institutes  and  centers,  UC
Berkeley is making a conscious and targeted effort in helping the faculty,
postdocs and young entrepreneurs to bring their research to market. 
Along with UC Berkeley also UCSF and UC Davis have transformed their
innovation  ecosystems  and  adopted  entrepreneurial  and  venture
programs in order to boost the technology transfer. The latest initiative of
UC Berkeley is to nominate a Chief Innovation Officer whose role would be
to streamline and promote the innovation and entrepreneurship efforts on
campus. However, many initiatives at these public universities are at an
early stage, comparing to Stanford, whose innovation ecosystem has been
established  decades  ago.  That  explains  a  number  of  overlapping
initiatives and a somewhat confusing structure that may act as a barrier
for  the  scientist  entering  this  ecosystem  with  the  intention  to
commercialize a technology s/he has generated. 
There is a multitude of ways how the university supports the research
transition to the market. I will  present a few examples in some detail.
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Some  novel  formations  are  still  in  a  pilot  phase,  but  they  show  the
direction and trends in the development of the innovation ecosystem.
3.1.  Advancing from Basic to Applied Research – example 
of QB3 Pop Up Institute42
Quantitative Biosciences Institute (QB3) was created by the California
state legislature in 2000.  It is an innovation center made up of over 200
quantitative  biologists  at  three  northern  California  campuses  (UC
Berkeley, UC San Francisco, and UC Santa Cruz) working at the interface
of the physical and biological sciences.
Initially supported by a governmental grant of USD 4 million a year, the
funding today decreased to annual 800K, matched by the private partners
– donor funds and industry contributions. Private companies bring USD 50-
200K each in funding, some companies sponsor events and conferences.
One  part  of  QB3  hosts  the  core  facilities  and  carry  out  the  (basic)
academic research. Another one, InnoLABs, created to promote applied
science, also provides assistance to the startups.
The QB3 launched its pop-up institute 5 years ago as an attempt to
bring  researchers  together  to  work  on  a  multidisciplinary  problem.
According to Ioana Aardei, Entrepreneurship Program Manager at QB3, the
concept arised from the fact that it is very expensive to set a “proper”
institute. The pop-up institute allows principal investigators to work part
time on a specific problem while staying in their laboratories.  
Calico (an Alphabet company) funded the first symposium on aging.43
That presented the projects in the field of basic research. Five years later,
the second symposium advanced to the area of applied research. Part of
was already devoted to technologies taken over by startups that pitched
their  projects  to  the  investors.  It  demonstrated  that  in  the  five  given
years,  the technology field  had matured.  In  the next  5  years,  another
symposium  may  take  place,  but  already  involving  the  FDA  (Drug
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Development  and  Approval  Agency)  discussing  drug  profiling,  bringing
reimbursement experts etc. in the field of aging.44
Following success of the initiative, QB3 has recently started a new pop-
up  institute  on  fibrosis,  thanks  to  a  donor  donation.  Next  considered
projects are “what is an inflammation” and “blood vessels exploration”.
Lessons learned: In order to foster the innovation and technology
advancements there is no need to create fixed costly structures.
Fluid organizations with a clear objective and limited time frame
(max 5 years) can offer an inexpensive and dynamic solution. 
3.2.  Deployment of a Mix of Complementary Support 
Mechanisms – example of CITRIS  
The  Center  for  Information  Technology  Research  in  the  Interest  of
Society (CITRIS) is  another center created in 2000 by former California
governor  Gray  Davis. The  mission  of  the  Centre  and  the  associated
Banatao  Institute  is  to  create  the  information  technology  solutions  for
society’s most pressing challenges and to shorten the pipeline between
world-class  laboratory  research  and  the  development  of  applications,
platforms  and  companies. From  concept  to  prototype,  the  CITRIS
innovation ecosystem includes:
 competitive seed funding, 
 specialized testbeds, 
 Marvell Nanofabrication Laboratory, 
 CITRIS Invention Lab, and the 
 CITRIS Foundry startup accelerator. 
CITRIS  unites four  University  of  California  campuses:  David,  Merced,
Berkeley  and Santa Cruz.  The fact  that  there are four  campuses each
having their own center of excellence and specialization is helpful when
discussing  the  cooperation  with  big  companies/corporations  –  it  is  a
strength that distinguishes the center from the private universities. In its
vision  for  2025,  Costas  Spanos,  the  Director  of  CITRIS,  focused  on
interdisciplinary  technologies.  The  center  already  operates  at  the
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intersection of disciplines and in 2018 has extended its activities to the
policy field.45
The CITRIS Foundry is an accelerator for deep technology startup
companies—those  founded  on  the  basis  of  scientific  discovery  and/or
meaningful,  hard-to-reproduce  technological  innovations  with  the
potential to transform society. The Foundry's accelerator program offers
startup teams a variety of valuable resources that include flexible maker
space, access to the Marvel Nanofabrication Laboratory, wet lab space in
the  QB3  Stanley  Hall  Garage  and  MBC  Biolabs  in  San  Francisco.  The
Foundry  pays  for  the  startup  teams'  use  of  space  for  the  12-month
program. Over the last five years, the Foundry has expanded its portfolio
from predominantly IT-focused startups to teams working at the frontiers
of  gene  editing,  artificial  intelligence,  biomedical  technologies,
programmable hardware and energy systems. Thus far, the Foundry has
supported 42 teams,  the vast  majority  of  which (79%) were driven by
graduate students. 
The  institute  (foundry)  takes  a  small  amount  of  equity  from the
participating companies. Intentionally, the amount of equity retained has
been kept small, as the objective is not to stifle innovation, but to give
back to the campus in the event of success.
Lessons learned:  In order to maximize the effect of innovation
and technology transfer, the mix of tools and mechanisms brings
added  value.  CITRIS  combines  seed  funding  with  accelerator
facilities  and  access  to  laboratories  as  many  other  successful
accelerators in the Bay Area (for example, IndieBio).
3.3.  University Supported Accelerator - example of Skydeck
46
Skydeck  is  the  largest  startup  accelerator  at  UC  Berkeley  campus.
Skydeck was founded six years ago but has grown significantly in the last
3 years. Since 2018, Skydeck is fully industry funded. Its aim is to invest in
breakthrough  technologies.  While  for  certain  verticals  like  software
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Skydeck would request some traction from the companies in the form of
revenues and customers, biotech companies come to Skydeck at a very
early stage. 
Many companies participating in Skydeck have a connection with UC
Berkeley.  But  recently  Skydeck  started  to  accept  global  participants,
although  they  are  not  eligible  to  receive  the  funding.  By  the  end  of
program,  the  companies  develop  connections  with  UC  Berkeley  and
industry advisors, may employ the UC Berkeley postdocs to their company
and can benefit from the use of UC Berkeley laboratories under certain
conditions (SSUFIE agreement discussed later in the text). 
Selection  of  the  participating  startups  is  very  tough,  only  3,5%  of
applicants are selected. All projects are arranged by verticals (software,
biotech,  etc.)  and each vertical  is  evaluated by about  5 people.  If  the
project receives a good score, the team is invited to a first interview. Even
if  one person from the panel is  very excited about the project,  it  may
result in the project  passing the preselection. 15-20% of the companies
that apply are admitted to the first interview stage that may be conducted
remotely.  During  the  interview,  25  minutes  are  devoted  to  the  team
composition and 10 minutes to the project presentation. Very much focus
is on the team: how committed and invested in the project members are.
The  interviews  are  done  by  the  committee  comprised  of  VC,  industry
partners and Skydeck staff. 
About  30% of  the  companies  will  make  it  to  the  second  interview,
where they have to be present at Skydeck in person. During the second
interview  the  focus  is  on  technology:  for  more  indepth  discussion  the
faculty member,  specialist  in the technology or member of  a company
working in this field may be invited. The potential funding sources and
existing  competition  are  also  evaluated.  If  necessary  due  diligence  is
performed and/or additional questions are mailed to the CEO. About half
of the second round participants will make it to the finals (around 100).
The best 20 will be funded. The selection takes place twice a year.
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Recently  Skydeck started to  invest  in  the top startup companies  at
their accelerator via the created fund. Core cohort is funded in the amount
of 100,000 USD for the equivalent of 5% equity at a $2 million cap (SAFE
note)47. Fund is legally separated from Skydeck and the money from the
fund  is  distributed  via  the  board  of  directors.   Any  profits,  when  the
startups are sold or go public, will be split 50-50 with UC Berkeley. 
The  success  is  measured  whether  the  company  managed  to  raise
money.  After  graduation  from  Skydeck  about  60-70%  of  companies
receive additional financing and this is a very high percentage.48 The high
success rate of Skydeck is explained by three factors: proximity to the
university  and the  possibility  to  use  its  resources;  proximity  of  Silicon
Valley; focus on the cutting-edge technology. 
Lessons  learned:  There  is  a  general  trend  that  with  time  the
(successful)  accelerators  grow  in  size  (number  of  startups
accepted) and also create the venture capital funds to secure the
early stage investments for the most promising companies.  An
interesting feature of Skydeck VC fund is that half of its proceeds
will go back to the University of California. 
 
3.4.  Shared Special User Facility (SSUFIE)- example of UC 
Berkeley
SSUFIE  is  a  new  structure  introduced  by  UC  Berkeley  for  the  new
technologies to be tested in the laboratory in return to a fair market value
fee,  while  ensuring  environmental,  health  and  safety  compliance,  and
managing the conflict of interest. 
SSUFIE closes the gap between the research done in laboratory and
start of the product development in the startup. It was destined for the
early stage (pre-product sales) startups affiliated to one of the university’s
accelerators. It satisfies the need of the students, especially those who
already have been working at UC Berkeley laboratories, to continue using
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the laboratory for their product development. Prior to the pilot, it was not
allowed  due  to  concerns  over  conflict  of  interest,  non-profit  rule,
environmental and health control considerations, even if laboratory had
spare  capacity  and  was  willing  to  accommodate  such  work.  The
participating startups are required to  pay market  rates  for  the (tightly
defined and time-limited) use of faculty lab facilities. Proceeds from this
program support research and education in the SSUFIE faculty labs and
corresponding  departments.49 It  is  a  win-win  project,  as  the  laboratory
receives extra funding but the startup’s founder can continue working in
the known conditions  (often it  is  the laboratory where the founder did
research previously, as a PhD or a postdoc), but pursuing research with a
commercial intent.
The  SSUFIE  agreement  fall  under  novel  intellectual  property  (IP)
provisions called  joint ownership with university commercial forbearance.
To  account  for  this  exceptional  use,  IP  solely  invented or  authored by
startup employees under the SSUFIE agreement is jointly owned by the
startup and the university. However, the university agrees to forbear from
commercially  licensing  the  IP,  and  can only  use  the  IP  for  research,
education and non-profit purposes. In summary, the startup has exclusive
commercial  rights  without  the  need  of  an  university  license.  These  IP
provisions are unique and approved by the University of California Office
of President as an exception to University’s IP policy.
Mike  Cohen,  head  of  Technology  Transfer  Office  of  UC  Berkeley
explains50 that the program has faced initial concerns similar to the ones
that newly created accelerator Skydeck faced back in 2012: that it can’t
be done and shouldn’t be done. In both cases decisive argument was that
these types of initiatives are a part of an educational process.
Mike Cohen makes it clear that it is not the intention to overrun the
university  IP  rights  and  the  mission  of  basic  research  with  SUFFIE
agreements. It is an exceptional opportunity and will remain as such. In
numbers, since the launch in 2017 there were 35 enquiries about such an
agreement and 8 SSUFIE agreements were signed. So, the size is very
small  comparing  to  the  size  of  the  University.  The  pilot  is  considered
34
successful and there is an interest at other campuses to implement the
SUFFIE idea, too.
Lessons  learned:  Pilot  of  the  UC  Berkeley,  SSUFIE  agreement
gives an opportunity to a startup to “rent” the place in laboratory
of its choice, keeping the IP rights. The laboratory benefits from
the additional funding while startups have the lab space where
they can develop the technology for commercial use.
3.5.  Entrepreneurs in Residence Program
The program “Entrepreneurs in Residence” is a new program at the
Institute of Innovative Genomics (IGI), academic research organization in
partnership  with  UC  Berkeley  and  UC  San  Francisco.  Susan  Jenkins,
Managing  Director  of  Institute  of  Innovative  Genomics  shared  her
experience and lessons learned managing the program.51
The funding of Entrepreneurial  Fellows Program came from a donor.
The concept of the program was to provide up to 250,000 USD for two
years to researchers who thought that their idea could be brought to the
market. The postdocs could use the laboratory and hire a technician under
this funding. It was meant to be a postdoc program where more applied
research/proof of concept studies were conducted. 
The  program  was  advertised  worldwide  but  the  response  rate  was
much lower than expected. IGI received only 10 applications, one from
India,  one  elsewhere  from the  US  and  8  from  UC  Berkeley.  With  the
hindsight IGI understood their mistake: as the program was focused on
the commercialization of the technology, researchers from outside did not
want to apply to the institute as complicated issues of IP transfer were
involved (need to split the pre-IP with the IP created during the program). 
What IGI did not anticipate was that both selected candidates would
incorporate  their  company  already  after  3  months  in  the  program (in
contrast  to  the  expectations  that  they  would  do  it  at  the  end  of  the
program).  After  6 months in  the program they started the talks  about
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licensing the technology. They wanted to use fellowship money to do it.
That was of course not an option. Next, the researchers came up with the
idea of leasing laboratory space and work on their company in the “free
time”. As they would lease laboratory on commercial terms, it would allow
them  to  own  their  IP.  This  idea  was  again  declined  by  the  due  to
difficulties to split IP created during the fellowship and the one created for
the company. One of the researchers finally raised external money and
also  got  SBIR  funds  and  after  graduation  from  the  program  devoted
himself fully to the company. Other one managed to split two components
of his study and worked on one component under fellowship in the IGI
laboratory, and the other one in the leased laboratory of IGI, creating his
own IP.  Researchers  also had tensions with  Intellectual  Property  Office
(IPIRA), as they were hoping to get exclusive license on their technology,
which  IPIRA  was  not  willing  to  provide   (licensing  of  a  breakthrough
technology, can bring millions to the university if non-exclusive rights are
provided. As small companies founded by researchers are very likely to
fail, the university hesitates to grant them exclusive right for the use of
technology). 
Based on this  experience,  Susan suggests that a one year program
would be sufficient and more milestones about what researchers should
achieve in  6,  9  and  12  months  should  be  defined.  Also  the  timing  of
incorporating a company needs to be discussed upfront. 
The example clearly shows mismatch of expectations for the program:
while funding partners wanted that the research was done, and envisaged
licensing only at the end of the program, the researchers saw a program
as the help to start their private business and tried to find a way to create
IP that were not locked by the university. 
Lessons learned:  The attempt to bring technology towards the
market with the entrepreneur in residence program had yielded
mixed results. With the hindsight one year residency would be
sufficient  and  more  specific  milestones  determined  in  the
beginning  of  the  program.  The  potential  conflict  between
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research  and business  interests  are  clearly  highlighted  in  this
case,  raising  the  question  about  a  “traditional”  research
institution  being  the  right  place  to  bring  technology  to  the
market.
3.6.  University Education and Support Programs 
In  each  university  various  educational  programs  are  offered  to
scientists and students considering entrepreneurship. The few programs
that I had a chance to audit were FORM and FUND offered by Berkeley
Law;  Startup  101,  offered  by  UCSF  Medical  School;  Management  of
Technological  Innovation  course,  offered  by  Sutardja  Center  for
Entrepreneurship  and  Technology;  and  Berkeley  Post  Doctoral
Entrepreneurship Program (BPEP).  
At  BerkeleyLaw,  FORM  and  FUND  series  teaches  the  core  legal,
financial,  and  organizational  aspects  of  starting  and  scaling  a  new
business  by  leading  Silicon  Valley  attorneys,  entrepreneurs,  and/or
venture capitalists. The course mixes people from engineering, technical,
law and business backgrounds and provides free incorporation services
and office hours with the advisers and venture capitalists for the startups.
Startup 101 offered by UCSF Medical School is an experimental, team-
based class that  covers  the topics  important  to starting a scalable  for
profit venture, teaching how to recognize a business opportunity, to do
market  research,  develop  business  plans  and business  models,  clinical
development,  regulation,  how  to  get  reimbursement  from  insurance
companies,  intellectual  property,  building the team, financing strategy,
budgeting, sources of capital and more. 
Management  of  Technological  Innovation  is  a  course  offered  by
Sutardja  Center  for  Entrepreneurship  and  Technology,  which  prepares
graduate students and post-doctoral students across all disciplines to be
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able to translate technical work into value as a new venture or in industry
settings.
Berkeley Postdoctoral  Entrepreneur Program (BPEP) aims to foster
entrepreneurship  in  the  UC  Berkeley  postdoctoral  and  graduate
community  by  providing  tools,  mentoring,  and  a  platform for  science-
business communication to enable research innovations to move into the
marketplace.  
Besides,  some  UC  Berkeley  centers  (like,  for  example,  Berkeley
Sensor  and  Actuator  Center  BSAC  founded  by  National  Science
Foundation, UC Berkeley and UC Davis) have the Visiting Industrial Fellows
programs, where industry representatives join the lab and carry out their
research. The Fellows are free either to join an ongoing research project
or launch a new one.52 
Lessons learned: The programs on campus help students with the
scientific background to understand the basic business concepts
and present them with career opportunities beyond academia. 
3.7.  Program that Matches the Technology and MBA 
students - Cleantech to Market 
The program was launched 10 years ago at the Haas Business School
at UC Berkeley. It is privately funded by donations from corporations, non-
profit  organizations,  and  former  alumni.  It  greatly  benefits  from  the
location  in  Berkeley  and  the  proximity  of  Lawrence  Berkeley  National
Laboratory, Hass Business School, other Berkeley faculties and the Silicon
Valley where solar and battery companies are concentrated.
According to the Director Brian Steel53, the program is unique. The only
place where a somewhat similar program exists is the MIT. But in the MIT
students  work  on  the  preselected  technologies  and  do  not  actively
participate in their selection. 
The main stages of the program are technology application selection,
building  a  team,  updating  the  syllabus  (adjusted  on  the  basis  of  the
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technology selected for the current year), followed by 15 weeks of class,
for which a credit is awarded, and a public symposium. The selection of
projects  is  national  wide,  including  several  partner  organizations  like
ARPA-E, Lawrence Berkeley National Lab, and top-tier universities. 
The selection is focused on the technology that is currently between
TRL54 stages  3-6  (between the  first  tests  of  the  proof  of  concept  and
tested  prototype).  Cleantech  to  Market  (C2M)  cannot  accept  the
technology in too early a stage, as it needs data to do technoeconomic
modelling. C2M searches for core technologies that are already risk-free,
sufficiently robust and proven with respect to function.
There are three phases of evaluation of the technology. The first one
is  internal,  when  C2M  talks  to  people  who  know  about  the  specific
technology (both at university and industry) to validate the idea. Then, an
external advisory board consisting of executives (VC, investors) and prior
year students evaluates the technological potential. 
Next, the team leaders are selected and they choose the technology
they want to work with. Other students join and, normally, at least one of
the  team  members  has  a  technical  background.  Based  on  4-6
technologies  selected,  the  syllabus  gets  adapted  and  specific  guest
speakers are invited based on the needs of teams. 
During  their  assessment,  students  will  have  to  provide  40-80
possible scenarios of use of technology that later will be cut down to 12
and then to 3, understand the competitors and interview the players in
the  market,  potential  users  and  investors,  conduct  technoeconomic
modelling and prepare a pitch. 
The program provides a win-win situation both to the startups and
the students. The startup gets out of the program about 1000 hours of
free  work  on  developing  viable  business  models,  market  reports,
interviews and analysis of the markets and competitors. The student gets
out of program the real business case to work and practice on, sometimes
subsequent employment by startup, particularly if the startup managed to
raise funds.
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Lessons learned:  C2M is a win-win program. Startups receive up
to 1000 hours free marketing research and students get hands on
experience of the market.
4. University-industry  collaboration and its  role  in  bringing  the
research results to the market
The university-industry ties are historically strong in the Bay Area. In
contrast to Europe and Japan, the faculty in the US are not civil servants
and thus are allowed to engage in private sector activities. In exchange of
their involvement in the industry, they may receive a compensation for
consulting  services  or  a small  part  of  equity  for  being at the advisory
board for a startup. 55
If  we  look  at  the  historical  examples  of  collaboration  between
university and industry, already in the 60s, “Terman (provost of Stanford
university  since  1955)  encouraged  Stanford  faculty  to  serve  as  paid
consultants  to  corporations,  a  shrewd  directive  that  bridged  the  gap
between academia and industry.  He believed that it  would not only be
beneficial  for  professors  to  keep  up-to-date  on  industry  interests  and
future directions, but it would be an effective vehicle to provide research
funding and fellowships for Stanford’s most promising students. Terman’s
policy is so valued among faculty that, to this day, they credit it as the
single  most  important  contribution  of  the  academic-entrepreneurial
environment”.56 However, while industry played a significant role in the
private  universities,  in  public  ones  involvement  with  the  industry  was
taken  with  a  degree  of  caution.  The  concerns  of  diverting  the  basic
research and resources from the “core” research and education mission
were the reason for that.
With the decrease of federal funding for the public universities over the
recent years (the funding of University of California had dropped almost
by one third since 2000), the role and participation of industry in public
universities  increased.  A  set  of  tailored  collaborative  models  emerged.
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Besides traditional sponsored research collaboration, other forms coexist:
industry membership scheme, single lab contract research, joint research
centers,  entrepreneurs-in-residence,  competitions  and  hackathons  for
students, sponsored conferences and workshops. 57
4.1.  The Sponsored Research Agreement
The  core  university/industry  agreements  are  sponsored  research
agreements  and  facility  use  agreements.  The  sponsored  research
agreement is prepared with the help of the Intellectual Property Office or
similar  organization of  the university.  Contribution  from the industry is
normally higher under the sponsored research agreement, comparing to
the gift funding (see item 4.3), but in contrast with the gift or donation,
contractual  obligations  are clearly  outlined and it  is  expected that  the
University  (through  the  work  carried  out  by  University  faculty  and
students) helps the sponsors accomplish their goals.
Depending on the needs of laboratories and industry the concluded
agreement  could  be  a  master  agreement  (covering  broad  scope  of
cooperation, including one or more laboratories and institutes) or a tight
scope agreement, limited to specific research and/or specific laboratory.
For  IP  developed  under  sponsored  research  agreements,  ownership
follows inventorship and authorship. If the sole inventors or authors are
university  employees,  then  the  university  owns  any  associated  IP.
Typically, sponsored research agreements stipulate that the university will
give the corporate sponsor the first right of offer to exclusively license the
associated IP rights. 
The initiative of collaborative sponsored research comes from both
parties:  on  the  one  hand,  industry  may  seek  collaboration  with  the
laboratory after attending a conference or reading a publication. On the
other side, laboratory or rather principal investigator (PI) or students may
reach to the industry with the intention of having access to funds for the
research. 
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“A  typical  sponsored  project  for  research  begins  with  a  faculty
member becoming interested in the study of a particular phenomenon, for
example, the genome of crop plants. The faculty member realizes that she
needs to buy materials and equipment and hire graduate assistants to
engage in this research project. Since the faculty member’s department
does  not  have  enough  funds  to  support  this  research  internally,  the
faculty member looks for an external sponsor, also interested in studying
the genome of crop plants”.58 The faculty members generate leads and
develop a network through conferences, publications and presentation of
their work.
A  few  interviewees  have  noted  that  the  corporations  have
recognized that they are not able to innovate in house. The big companies
with the hierarchical structure and their business/profit-oriented approach
are not  able  to  ensure  (radical)  innovation  inhouse.  The structure  and
setting of the internal organizational processes stifle innovation. It needs
external,  free and creative space to make the innovation happen. And
they can find this place in the university, hence the increased interest for
the collaborative sponsored research.
Industry  provides  the  funds  to  do  the  research  and  University
provides  the  laboratory,  PI  and  students  to  do  the  work.  To  have  an
agreement,  both industry and laboratory need to have “a match”,  the
research  should  be  of  interest  to  the  PI  and  also  she  has  to  have  a
capacity (space) to do it. If research could result in a product, the IP rights
licensing agreement is made. The university is doing research and only
research work.  Once the research is entering the stage of the product
development the research is handed over to the company.59
“Increased  corporate  sponsored  research  results  in  more  mature
inventions that companies are likely to want to license, compared to early-
stage inventions that are far from being a commercial product”60, state
Director  of  IPIRA,  Dr.  Mimura  in  the  Report  on  Entrepreneurship  at
Berkeley.  The  industry  sponsored  research  has  grown  8-fold  at  UC
Berkeley since IPIRA was established in 2004. On average, about 15-20%
of  new invention  disclosures  are sponsored by  companies  that  want  a
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license to the IP and, therefore, are on board to pay the costs associated
with IP protections.61 At UC Berkeley sponsored projects are short term
activities typically lasting from one to five years. Sponsored projects may
be renewed and continued for a longer period, but there is always an end
date.  The funds provided  by  the sponsor  are  also  limited  to  a  certain
amount. The sponsor may choose to give additional funds over time, but
typically  there  is  a  finite  amount  of  funding  provided  for  a  sponsored
project.
Facility  use agreements aren’t  collaboration  agreements;  instead,
they are designed for the commercial use of university resources that are
set-up to be regularly used by companies (and companies pay user fees
for the commercial use). Therefore, any IP developed under a facility use
agreement  is  presumed  to  be  solely  invented  or  authored  by  the
company's  employees,  and  accordingly,  the  company  solely  owns  the
associated IP rights. SSUFIE agreements are a specific form of facility use
agreement that is at pilot phase at UC Berkeley (described in chapter 3.4.)
4.2.  Individual faculty funding – example of Energy 
Biosciences Institute
Another  type  of  university/industry  relationship  is  the  individual
faculty funding. One example of it is the British Petroleum (BP) funding of
Energy  Biosciences  Institute  (EBI)62.   Craig  B.  Vaughn,  a  process
technology advisor for the Vice President in the BP, was responsible for
the IP strategy at the Energy Biosciences Institute (EBI) and was directly
involved in the setup of the institute.63  He explained that back in 2007, BP
decided to get into the biofuel and the renewables fields but did not have
the required know-how inside the company. BP specifically looked for the
academic  environment  as  they  felt  that  in  their  business  oriented
company  (aiming  to  meet  quarterly  goals  etc.)  and  considering  their
limited expertise in the field, they could not create the environment that
stimulates research. BP put together a proposal and sent it to a number of
universities (including MIT and UC Berkeley). By assessing the universities
43
by  the  different  criteria:  specific  expertise  in  the  field,  analytical
capabilities and IP terms, UC Berkeley was chosen. Energy Biosciences
Institute  (EBI)  was  created  under  an  agreement  with  British  Petrolium
(BP), which contributed 50 million yearly (35 million for basic research and
15 million for BP core research) over 10 years.64 
BP  hoped  that  the  cohort  of  researchers  would  achieve  the
breakthroughs in the renewable energy field in the “open section” of the
institute and then the technology that  would be moved to the “closed
section” for further development and commercialization. In addition, BP
Venture Group was created with the purpose to fund the promising ideas
that could be commercialized in the core areas of BP interest. However,
according to Susan Jenkins, former managing director of EBI, not a single
project was funded by this VC group. There were few spin-offs from the
institute but not in the core fields of interest to BP and therefore they
were not funded by them.
The important aspect of collaboration between BP and the university
was that there was a lot of interaction between BP and researchers. It was
not a situation in which a PI, after winning the grant, would spend two
years  at  the  laboratory  without  interacting  with  the  company.  Vice
President, process technology advisor, and few staff at BP regularly kept
the  research  on  track.  Monthly  seminars  were  organized,  BP  regularly
attended  the  research  group  meeting  to  see  where  the  research  was
going.  Unfortunately,  BP  started  to  back  up from collaboration  after  8
years  due  to  Golf  Coast  oil  spill  and  decrease  in  oil  prices.  They
renegotiated  the  contract  keeping  the  same (beneficial)  conditions,  as
regards  to  patenting  and  licensing,  but  significantly  decreased  their
contribution to 2,5-5 million USD per year.
This  cooperation  was  beneficial  for  University  of  California.  The
contributions of BP were more than 300 million USD to the EBI since 2007,
an amount that the EBI would never get from Federal funds. BP funded
100 million USD purchase of materials and instruments, basic research,
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hundreds of graduates and all patents. EBI funded more than 75 research
programs or projects in areas such as biofuels, biomass and   renewable
chemicals. The cooperation with EBI resulted in 80 patents in 8 years, paid
by BP, but BP did not directly commercialize any of them and the research
was never passed on to the “closed” part of BP.
The terms of agreement were also favorable to the BP. The contract
gave  the  opportunity  for  BP  to  opt  for  exclusive  license  at  a  pre-
negotiated rate. (However, the contract still  contained a clause that, in
the  case  of  technology  that  would  bring  significant  royalties,  the  pre-
negotiated rate could  be renegotiated).  Looking  in  retrospect,  Craig  B.
Vaughn thinks that if BP were only be interested in the commercialization,
it  would  be  more  beneficial  to  acquire  a  company  than  pursuing
collaboration with the university. But the reason of collaboration was that
BP wanted to address a broader issue and make an impact in the biofuel
field. It wanted to participate in the food and fuel debate and other social
economics work as it was not clear, at that moment, where the US policy
in this field was heading. EBI provided a perspective on the above issues
that was a value added for the BP. 
4.3.  Industry Membership Programs and Gift Funding
Industry  Membership  Programs  link  academy and  industry.   The
contribution from the industry in the amount between 50,000 and 300,000
USD, with 100,000 USD on average goes to the centers or institutes. In
return,  the  sponsoring  company gets  direct  access  to  different  faculty
members, the opportunity  to attend exclusive events, have a firsthand
non  contractual  access  to  the  research  findings  and  also  access  to
recruitment  of  graduates.  Let’s  take  the  Center  for  Long-Term
Cybersecurity  at  UC  Berkeley  as  an  example.  It  is  a  translational  hub
created between research and industry funded by a private foundation.
The cybersecurity issues are spread across the UC Berkeley campus as
they are  present  in  many disciplines  (sociology,  school  of  information,
etc).  The  Center  helps  to  bring  all  these  competencies  together  and
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provides  an  entry  point  to  the  industry.  After  having  established
relationship  with  multiple  faculties,  in  one  or  two  years,  the  industry
partner may decide to focus on sponsoring one specific faculty.
The most  generous form of  funding,  gift  funding,  means that  no
requirement can be imposed by the industry, there are no deliverables
and no contract.  This  is  of  course  the  preferable  collaboration  for  the
faculty.  It  should  be said that,  informally,  the faculty  still  provides  the
feedback  to  the  company  and  may  share  research  results.  The
relationships  established allows the company to be “the first  to know”
about research developments. It has been noted by the faculty, that “gift
funding”,  or  donations,  became  increasingly  rare,  as  more  and  more
contributors  are looking for  part  of  the equity  or  some return  to their
investment. 
4.4.  Institute as a Mediator Between Industry and Startups 
For the strategic alliances, networks and collaboration are crucial. They
are  formed  via  internal  referrals,  industry  networking,  conferences,
publications, proactive contacts, VCs, investment bankers, and unsolicited
inquiries. One of the missions of the Institute of Qualitative Biosciences,
QB3 (already presented in chapter 3.1), is to bring industry and startups
together, to introduce them to one another. If industry expresses interest
in the startup, the dialogue may start even at the incorporation stage of a
startup and, later on, based on the company’s development, it could lead
to  a  deal.  If  a  corporation  has  interest  in  a  startup,  the  Business
Development  team from the  corporationside  may  pay  for  the  pilot  or
licensing of the technology.
A strategic alliance or partnership with the founder, who stays either in
the university and continues the research work (this is described in more
detail  in  the chapter on university-industry relationship)  or  creates the
startup,  may  bring  access  to  new innovations  and  products  without  a
major  internal  investment.  It  allows  to  utilize  her  expertise  instead  of
building  an  internal  innovation  capacity.  Academical  environment  and
newly created startups are more open and their culture is more supportive
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to  cultivating  breakthrough  ideas  that  entail  higher  risk.  The  strategic
alliance may help the large company to reach new markets, enter related
businesses or  expand the internal  portfolio  and this  is  the reason why
corporations  collaborate  with  research  institutes  at  the  leading
universities.
The startups benefit from strategic alliances financially, by attracting
the  technical  expertise  to  develop  a  product,  as  well  as  industry
knowledge  on  how  to  develop  and  commercialize  products. 65 By
collaborating it  may also benefit from the corporation’s  existing clients
portfolio.
Institute  of  Qualitative  Biosciences,  QB3,  assists  startups  from  the
incorporation stage (startup in the box) that resulted in incorporation of
650 companies. It  helps with sorting out their IP issues and give other
advise.  Some  companies  come  for  consultation  only  once  and  never
again.  Others  have  continuous  collaboration  with  QB3.  Participation  is
voluntary  and startups are free  to participate  in  other accelerators,  or
programs.
QB3 looks for the win-win approach and consent and interest from both
sides in the industry-university relationship.  Some industry partners just
want to be “in the know”. The collaboration goes throughout the year as
they want to be informed about the interesting subject/research that is
going on. QB3 makes introductions to the new teams and startups once
they see the technology that is  of  interest to its  industry partners.  By
means of partnerships, industry is looking for the new innovative solutions
and advantage of QB3. Through the institute, they can access very early
stage research that is not published or listed anywhere. One example is
the  collaboration  with  Procter  and  Gamble  (P&G).  QB3  introduced  ten
teams to P&G that presented their research projects and P&G followed
about half of them, which is quite a good indicator.
5. Lab to Market Transfer in Large Companies and Corporations
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The  industry  (by  that  I  mean  large  established  companies  and
corporations) traditionally  has been nurturing new technologies in their
R&D  labs.  The  iconic  example  is  the  Bell  Laboratories  -  an
industrial research and scientific development company owned by Finnish
company Nokia,  origin  of  radio  astronomy,  the   transistor,  the laser,
the photovoltaic  cell,  the charge-coupled  device,  the Unix operating
system,  and  the  programming  languages C, C++,  and S.  Nine Nobel
Prizes have been awarded for  work  completed  at  Bell  Labs  along with
three Turing awards.
Many companies tried to replicate the success of Bell Labs. But it has
proven  not  that  easy.  By  exploring  the  capacity  of  innovation  in  the
industry,  it  has  been noted that  big  corporations  may still  be good  in
incremental  innovation,  but  extremely  poor  in  radical  innovation.  By
examining  the  reasons  for  this  to  happen,  inflexibility,  organizational
culture, and misaligned objectives were noted.
The organizational cultures are very different in a startup and a large
company. As Steve Blank66 explains, the startup company is focused 100%
on  innovation  and  entrepreneurship.  By  its  definition,  the  startup  is  a
temporary  organization  established  to  experiment  and  innovate  until
finding the right business model that would allow it to scale and become
the large organization. Once becoming a large organization that already
found its business model it sets the goals of profitability and longevity. (It
is  especially true if  the founder is removed from the CEO position and
replaced by the “professional” CEO that is often the case of the venture
capital funded company).
If the large company tries to innovate, it may run out of business. It
does  not  mean it  cannot  innovate but  innovation  processes  should  be
done in parallel with the traditional operations. How? The answer ranges
from the innovative team within the organization to external innovation
hubs and companies’ acquisition. Below, I give examples of:
 Innovation inside the company – 5.1., 5.2. and 5.3.
 Innovation  outside (or  in  the margins)  of  the company –  5.4.,
5.5., 5.6.
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 Attracting external innovation – 5.7.
5.1.  Internal Innovation Team  - example of Telefonica
Telefonica67,  a  large communication company,  is  an example of  the
application of the Lean Startup methodology. Telefonica created a small
innovative  team  of  intrapreneurs  inside  the  organisation.  The  team
benefited from the access to high value assets of Telefonica: platforms,
infrastructures, global communication facilities, 350 million customers and
sales channels. Besides, access to relevant stakeholders was a lot easier
as the name of Telefonica itself opened many doors. 
Telefonica  faced  challenges  when  applying  Lean  Startup,  such  as
cultural  challenges,  finding  intrapraneurs,  corporate  politics  and
processes,  branding  issues,  and  project/product  transfer.  “External
startups  are  our  competition.  It’s  very  hard  to  do  things  better  than
startups.  The reason why the innovation  and development  department
exists,  however,  is  that we have many advantages that  startups don’t
have—our  network  capability,  customer  data,  and  our  distribution
channel. We develop innovations that leverage these three capabilities.”68
The study of Henry Chesbrough revealed several trends that should be
taken into account when considering innovation in the large organization:
 Innovation  through  a  small  group  of  people,  employees  of  the
company who are able to apply the Lean Startup approach to the
project in question;
 Importance of autonomy without looking for permission to spend
the budget and excessive reporting. As a team leader put it: “I try
to create the illusion that we are a startup.”
 Processes at large companies like Telefonica could affect negatively
innovation  projects:  “If  someone  in  a  startup  needs  to  build  a
prototype and needs three SIMs, they would just go to buy them at
any  store.  When  we  started  at  Telefonica,  we  had  to  use  our
purchasing process  and it  would  take three weeks  to  get  them.
Corporate processes can be a huge challenge and you have to work
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within those processes.” That finding is also supported by the Seco
Tools  team  (see  chapter  5.3)  who  noted  how  they  mentally
struggled at first to make the first orders without the approval of
the hierarchy. Only being placed in the US cocreation spate allowed
the team to take initiative and start takin initiatives without waiting
for approval from the headquarters.
5.2. Internal accelerator -  example of Area 120 in Google
There are few structures created by Google that address innovation
and help ideas to go out to the market. One of them is X or “the moonshot
factory”,  tackling radical  innovation projects that are independent from
Google. Another one is Advanced Technology and Products Group within
Google. And lately, the Area 120, where an internal Google incubator was
created.
Area  120  originated  from  the  idea  of  Google  that  employees  shall
devote 20% of their time to personal projects that might have value to the
company.  With  the  growth  of  the  company  though,  the  20% of  “free
creative” time slowly disappeared, replaced by the 120% working hours.
Despite  the  high  workload,  Google  wanted  to  stimulate  bottom-up
innovation and that was the reason for the creation of Area 120. Through
the creation  of  physical  space (that  exists  now in  three US cities  and
abroad) and by having access to Google experts and tools, it gives the
opportunities to Google employees to transfer their ideas into a product.
Anyone  can  apply,  being  the  engineer,  marketing,  sales  or  business
development person at Google. If the idea is accepted, the person gets a
team of 4-6 people, 6 months and some budget to work on the idea. 
“There have been many, many kinds of corporate incubators over the
years…We wanted to do something with a very specific Google approach
to it.” Employees “can actually leave their jobs and come to us to spend
100%  of  their  time  pursuing  something  that  they  are  particularly
passionate about,” explains managing director Alex Gawley”69.
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The type of people that Google 120 is looking for are those who are “in
love with the user centric products, have some vertical skills but mostly
horizontal skills, and have people centered approach” as Shelly Glennon,
partner  in  Google  says70.  On  the  question  of  selection  of  ideas,  she
emphasizes that “we really want you to identify the need, there are too
many solutions without a problem”. Selection comes down to three key
components: the team, with the focus on team diversity, the problem or
need they try to solve and the impact if the solution is provided.
It is expected that many ideas will fail, but a handful will succeed. One
successful  example is  a Grasshopper -  a smartphone app that teaches
users JavaScript coding via games. The timeframe for the projects is 3-5
years (In comparison, Google X, the Google spin-off that tackles radical
innovation projects, has 10-20 years project lifespan).
Lessons learned: The idea of Area 120 resonates with the claim of
Steve Blank, who says that out of 1000 people in the organization
there  are  50  innovators  hiding  somewhere,  so  one  needs  to
identify them and create a parallel structure to give employees
freedom to innovate. 
5.3. Sending a Team Overseas – example of Seco Tools
The  below  example  illustrates  how  the  big  company  enhanced  its
innovative capacity by sending small  teams of engineers overseas and
giving them a loosely defined task with a direction to come up with the
product in a six month time.
Seco  Tools71 is  a  Swedish  industrial  company.  This  traditional
manufacturing  company  wanted  to  modernize  and  explore  digital
direction. The question was “how?”. The solution that the company came
up with was to send a team of engineers to the Bay Area for 6 months,
giving them budget and a task. The task was defined broadly: to create a
new product  in  the  digital  area  by  employing  sensors.  The  team was
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selected in Sweden and “shipped” to Flex premises where they had to
work. They had online progress meetings with managers every 3 weeks. 
Flex is the SF Invention Lab and Micro-Factory, a prototyping, design,
and  small  batch  manufacturing  facility  in  downtown  San  Francisco.
Specifically  serving  early-stage  product  teams,  hardware  startups,  and
high-touch product designs, the Invention Lab allows a team to work on
products together on-site with Flex designers and engineers. Teams can
also experiment with materials, technologies and processes that disrupt
conventional thinking or business models. The space was ideal for early
proof-of-concepts and design exploration.
Flex is not a unique space in the Bay area. Other similar spaces are
located across the Bay area to help teams to test and experiment with
their technologies. The Seco team was assisted by the Enterpreneur in
Residence of Flex in their task.
Very early the team realized that they had to come up with a roadmap
and do something realistic, “basic” (“Minimal Viable Product” in the Lean
Startup terms) to cope with of the six month deadline target. They came
up with the idea of a sensor pen that is able to identify products in the
factory.  The pen (light,  plastic,  unbreakable  and  waterproof)  allows  to
scan products with a small chip attached to them. The application gives
specification of the part and also shows if it is compatible with other parts.
There is a high interest from customers in this product and the pen gets
ready for production. 
Lessons learned:  To create an innovative product, it is easier if
the team is externalized and put in a different environment or, at
the very least, operates on the margins of the big organization.
Flex premises was an ideal  place in this situation,  providing a
creative  collaborative  space  equipped  with  the  machines  and
entrepreneurs in residence, having knowledge and expertise. 
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5.4. The  Separate  Research  Facility  –  example  of  British
Petroleum Biosciences Center 
Oil  and gas industry is  particularly  inflexible  in  adopting the radical
innovations and it  is  particularly  difficult  and rare to witness the move
from research to market72. In the previous chapter 4.2. I described how
British Petroleum collaborated with the University of California, Berkeley in
setting out the Energy Bioscineces Institute. After severely reducing the
funding of the Energy Bioscineces Institute,  in 2015, BP established its
own independent research facility in San Diego, San Diego Biosciences
Center (BSC) that conducts  research aimed at accelerating the world’s
transition to a lower-carbon future. The Biosciences center functionally is
a division of  BP consisting of about 30 scientists. 
The BSC conducts research and development programs that can help
the  biosciences   make  larger  contributions  to  various  aspects  of  BP’s
operations,  including the production of renewable energy, oil and  natural
gas,  along with  the development  of  innovative and   efficient fuels  and
lubricants.  It  also  identifies academic  programs  that  can  complement
business needs. Among other capabilities, the BSC performs research on
microbiology,  metabolic  engineering,  microbial physiology,  metabolic
modeling, biochemistry, enzymology, fermentation and biogeochemistry. 
In  2017,  BP  Biofuels  formed a  joint  venture  with  Copersucar — the
world’s leading sugar and ethanol trader — to own and operate a major
ethanol storage terminal in Brazil. The joint venture has helped BP better
connect its ethanol production with the main Brazilian fuels’ markets. 
In the years ahead, the BSC plans to expand its research in areas such
as wastewater, remediation and enhanced oil recovery.   For example, it
plans to help BP make further progress on converting waste streams into
biogas, cleaning legacy industrial sites and producing oil more efficiently
from existing resources. 
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Another model that BP is using in getting new technologies onboard is
the venture capital model that attracts new companies. The BSC advises
BP Ventures on low-carbon and other investments. To date, BP Ventures
has  invested  more  than  190  million  USD  in  California-based
companies, partnering to bring clean technologies and other leading-edge
energy solutions to market. BP invests money in early companies, puts a
person on board and helps the company grow. It might take a share of 20-
25% of the company,  and if the company grows and the product interests
BP, BP could purchase its product at a discounted rate. If the company
really succeeds, BP may eventually decide to internalize it, by acquiring all
its  shares  (but  this  has  not  happen  yet).  A  similar  model  is  used  by
Chevron to fund startup companies.
5.5. Innovation Hub - example of Autodesk 
Companies create external innovation hubs open to new startups and
researchers  in  order  to  complement  their  knowledge,  attract  new
workforce  or  get  new  ideas  for  the  products.  Autodesk,  Inc. is  an
American multinational software corporation that makes software for the
architecture,  engineering,  construction,  manufacturing,  media,  and
entertainment  industries.  Autodesk  became  best  known  for AutoCAD
software,  but  now  develops  a  broad  range  of  software  for  design,
engineering,  and entertainment—and a line of  software for  consumers,
including Sketchbook. 
Autodesk  has  created  three  research/innovation  hubs  to  develop
research that may (or may not) result in a product. One hub oriented to
design and digital  manufacturing is in San Francisco, another one is in
Boston (architecture, engineering and construction) and a third one is in
Toronto  (oriented toward emerging  technologies,  AI,  robotics,  VR,  IoT).
Another  Autodesk  office,  in  Birmingham,  UK,  works  on  inventive
manufacturing solutions for the customers. They are all part of ARCO, a
special Autodesk division oriented toward innovation.
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These research/innovation hubs are the spaces where Autodesk and
their partners can explore and test new technologies. 
Through the Autodesk program residence in place,  external companies
have access to the tech space for a period of time ranging from a few
months to a year. They can use it at no cost, and keep their IP. In return,
Autodesk has the opportunity  to follow the frontline  research,  to show
their  consumers  that  they  take  research  seriously  and  want  to
continuously improve, in addition to establishing potential ties with the
customers. The residents in the program are accepted on a rolling basis
by  evaluating  the  relevance  of  their  technology  to  Autodesk’s  core
business.
According to Alyra Merchert73, the objective of this program is neither
to acquire the company nor its technology. Autodesk benefits from the
spill-over  effects  that  the  research  produces  and possible  partnerships
and collaborations that could result in working together. As this is purely a
research facility,  not all research results find their way into production.
Only  a  few  ideas  continue  to  be  developed,  maturing  in  scale  and
resulting in a product. The facilities provided by Autodesk are excellent to
test the technology out of the factory environment.
The result of residency program is that the companies leave with their
IP  after  having  tested  their  product.  Autodesk  does  not  acquire
technologies developed in the hub, it is rather a service to connect with
potential  customers  and  create  an  image  of  a  research/innovation
oriented company.
Lessons  learned: Autodesk  is  yet  another  example  of  created
collaborative  working  space  where  one  can  explore  and
experiment  with  building  new forms  of  tools  and  mechanisms
without disrupting large companies’ operating cycles. 
5.6.  JLABS - Johnson and Johnson Innovation (J&J) labs 
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JLABS San Francisco74  innovation center works as an external center –
independent innovation hub of Johnson and Johnson, medical devices and
consumer  goods  corporation.   It  hosts  29  independent  companies  (in
2018).  JLABS are life  sciences incubators  –  the companies  use the lab
during 6-9 months, and can keep their own IP. No equity is required for
participation, so “no strings are attached”, according to James Viola, head
of JLABS SF. Besides the use of the “wet lab”, JLABS helps new companies
to navigate in the vast universe of Johnson and Johnson and foster long
term relationships with innovators in healthcare.. JLABS serve as an entry
point. 
JLABS  are  reinforced  with  the  JJDC  that  is  a  corporate  VC  branch
investing in bio companies that is involved into all stages of investment
from seed to series A, B and beyond75. The corporate VCs understand the
market and may be open to invest in the technology when sufficiently
mature (that of course is good if it matches the objective of the founder).
JJDC works closely with the innovation center colleagues, covering each
therapeutical  area  in  R&D,  evaluating  the  process  and  deciding  if  the
technology  is  ready for  investment.  The JJDC aims to  form a strategic
partnership with the new companies that go beyond the venture investor-
company relationship. JJDC always takes a seat at the board of the newly
invested  company.  In  Vijay  Murthy’s  (head  of  JJDC  experience76)  view,
companies  tend  to  do  better  with  corporate  investors  than  traditional
ones, as JJDC provides expertise, know-how and introductions specific to
the industry.
Another department, Johnson Business Development, deals at the late
stages of development. They focus on mature companies that potentially
could  merge  with  or  be  acquired  by  J&J  and  also  takes  care  of  the
licensing deals.
Lessons learned: By providing the lab space for innovation and 
experimentation, JLABS not only supports new companies but 
also scouts them for potential VC investment, making sure that 
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they detect the potentially interesting companies ahead of the 
market.
And lastly, one can consider merger and acquisition (M&A) strategy and
strategic partnerships in creating innovative products and bringing them
to the market.
5.7.  Acquisitions as a Way to Move Forward
The acquisition of new technologies versus developing the innovation
in-house  is  a  popular  strategy.  It  is  believed  that  startups  are  better
placed in  “de-risking” innovative technology.  However,  the acquisitions
are not unproblematic. The internal innovation department may have a
hard time to accept the startup’s technology and team and that could
create an internal conflict. By buying outside, the companies are trying to
buy reduced risk and to buy time. But divisional managers sometimes are
not  incentivized  to  implement  the  innovation  proposed  by  external
innovative teams. As a result, when acquiring a startup, the best way may
be not to integrate the startup, but let it act independently and continue
doing what they were doing before, with the condition that the startup
should be mature enough not to be fully absorbed by the big company77.
Sometimes a startup is acquired solely for the team competences in the
acqui-hiring acquisition (acquisition, which primary objectives is to acquire
the talent not the product itself).
6. The Role of Funding in Closing Lab-to-Market Gap
The early funding for the technological development can be provided in
terms  of  grants,  loans,  angel  and  VC  capital.  While  the  very  early
technology  is  mainly  supported  by  federal  grants  and  philanthropical
donations,  scaling  up  requires  angels’  and  venture  capitalists’
investments.  The  evolution  in  graphically  presented  in  Figure  6  that
illustrates the sources of capital for the cleantech, but which equally can
apply to other deep technologies.
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The “bootstrapping” means that the company tries to survive on its
own,  without  depending  on  external  funding.  Typically,  it  can  use  the
founders’  savings,  or  money  from  the  “family,  friends  and  fools”.
Sometimes, money can come from the “liquidity event” – if a founder sells
previous  company  or  receives  a  large  payout  from  a  stock  holding.78
“Bootstrapping” could be feasible for the company that does not require
laboratory  experiments  and  expensive  raw  materials  to  pursue  the
research and develop the product. In case of deep tech, while in principle
it is possible to find a “rent-free” laboratory for a limited period of time
(place in the wet-labs incubators),  the costs of  raw materials,  on their
own, may be difficult to cover by the bootstrapping. 
In recent years, venture capital funds have grown and so have their
investments. Seed and pre-seed rounds took place in situations that would
previously involve round A funding. Accelerators and angels stepped in to
fund seed startups. A new class of micro-VCs appeared, who make 25-500
K  investments.79 The  typical  investment  round  in  seed  stage  is  from
10,000  —  500,000  USD  from  angel  investors  and  around  $1M  from
venture fund, but usually no more than 3 million USD.80 
Figure 6.  “The Investment Gap That Threatens the Planet by Burger,
Murray, Kearney and Liquian, Stanford Social Innovation Review, Winter
2018
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Venture  Capitalists,  and  also  angel  investors,  have  strong
customer/market  considerations  in  weighting  whether  a  technology  is
ready to enter the market.  From the VC perspective,  the technological
potential is not the only key feature. The focus is on the startup potential
to scale and attract customers and revenue. The product/market fit is the
key concept for the Lean Startup method of Steve Blank that measures
the potential of the company to succeed in the market. Technology must
come not too early and not too late to the market and, most importantly,
the market should be ready to adopt it. If technology comes too early, it is
not able to attract customers and, if too late, the market may be already
saturated with developed (same type or alternative) technologies. 
The evolution in the sources of funding can be further presented 
assigning the sources of funding to technical and business milestones in 
the commercialization readiness level.
CR
L
Technical Milestones Business Milestones Funding 
Milestones
0 Research validated Opportunity validated: corp. 
license if applicable
Public research
grants
1 Startup and technology 
development plan
Startup created, 
management team. IP 
licenses, legal issues settled
Public/Private
2 Market and technical 
feasibility established 
Business plan validated at 
accelerator level
Public; Ph1 
SBIR/STTR *, 
other public 
sources
3 “Works-Like” laboratory 
proof of concept
Key corporate advisors in 
hand; pharma target 
validated
Public; Ph2 
SBIR/STTR*, 
other 
4 “Work-Like” operational 
prototype
Commercialization plan 
updated incl. competitive 
update; tech landscape; 
preclinical validation and 
safety profile
Public; Ph2 
SBIR/STTR, 
other
5 Operational product 
development and launch
Funding for 
manufacturing/organizational 
development; human clinical 
validation
Public; Ph2 
SBIR/STTR, 
other; Angel. 
Pharma: 
corp/VC/Angel
6 Sales/service/support/scaling $ 0-1 million revenues Angel/VC/Corp
7 Sales/service/support/scaling $ 1-5 million revenues Angel/VC/Corp
8 Sales/service/support/scaling $ 5-10 million revenues VC/Corp
9 Sales/service/support/scaling $ 10-25 million revenues VC/Corp
10 Sales/service/support/scaling More $ 25 million revenues Exit/IPO
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Figure 7. Sources of Funding at different CRL levels81
 * SBIR/STTR federal grants will be dealt with in the next section.
6.1. Federal Grants 
The two Federal  programs:  The Small  Business  Innovation  Research
(SBIR)  and  the  Small  Business  Technology  Transfer  (STTR)  help  small
businesses to develop inhouse research and development that has the
potential for commercialization by providing them funding. Their ultimate
goal is to stimulate technological innovation that is  in line with federal
R&D needs, increase the commercialization of  private-sector innovation
and  support  women  and  socially  and  economically  disadvantaged
persons.
Funds for the SBIR program come from eleven Federal agencies with
extramural  research and development  (R&D) budgets  that  exceed 100
million USD and which are required to allocate 3.2% (FY 2017) of their
R&D  budget  to  these  programs.  Each  agency  administers  its  own
individual program.
STTR's  most  important  role  is  to  bridge  the  gap  between  the
performance  of  basic  science  and  the  commercialization  of  resulting
innovations. Central to the program is the expansion of the public/private
sector  partnership  to  include  the  joint  venture  opportunities  for  small
businesses  and  nonprofit  research  institutions.  The  Small  Business
Technology  Transfer  (STTR)  requires  participation  of  the  research
institution. 
Funds for STTR program come from the five82 Federal agencies with
extramural  research  and  development  (R&D)  budgets  that  exceed  1
billion USD and are required to reserve 0.45% of the extramural research
budget for STTR awards to small businesses. These agencies designate
R&D topics and accept proposals. 
Both programs are structured in three phases:
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Phase I. The objective of  Phase I  is  to establish the technical  merit,
feasibility, and commercial potential of the proposed R/R&D efforts. Phase
I awards normally do not exceed 150,000 USD total costs for 6 months.
Phase II. Is a continuation phase of Phase I. Funding is based on the
results achieved in Phase I and the scientific and technical merit and the
success rate normally increase from 12-13% to 25-30%.  Phase II awards
normally do not exceed 1 million USD total costs for 2 years.
Phase III. The objective of Phase III is for the small business to pursue
commercialization objectives resulting from the Phase I/II R/R&D activities
but the SBIR/STTR program does not provide funding for that. At this point
companies  must  be  able  to  raise  funds  from  angels  and  venture
capitalists.
Both programs are very competitive and the first funding is awarded
only to 12-13% of applicants. I have met a few deep tech companies that
received SBIR/STTR grants.  These programs are highly  valued,  as they
provide funding in forms of grants. So, unlike the venture capital, they do
not require the company’s founder to give up part of the equity in the
company. The agencies do not get involved in the management of the
company. Normally, these grants are not only one type of support that
companies receive. Other types of support involve admission to Cyclotron
Road program, use of Shared User Facilities, participation in QB3 or FAST83
programs. 
However, the grant may also become an obstacle for the successful
development of the company as it happened with Correlia Biosystems, a
bioengineering company84. Having received 600,000 USD SBIR grant from
NIH in 2014, the company quickly discovered that, in order to enter the
market,  they  needed  to  pivot  significantly  from  their  original  idea.
However, for the next two year, the company remained “locked” to the
grant  it  had  received  and  the  type  of  research  it  had  committed  to
conduct and were not being able to pivot until the end of the grant.
6.2.  Accelerators’ micro funds
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In the past few years, accelerators started to form small investment
funds  to  help  their  own startups  in  exchange of  equity.  Typically,  the
accelerators provide about 100,000-120,000 USD investment in the form
of  a  standard  SAFE  note,  in  exchange  for  an  equivalent  of  5-7%  of
company’s equity.
The  UC Berkeley  largest  accelerator,  Skydeck,  has  formed  its  Fund
about a year ago. The Fund is created in the way that 50% of proceeds
(profit) will be given to UC Berkeley. The founders claim that even by very
pessimistic scenarios, the fund will bring profit to the university. 
The micro funds help to fill  the gap in funding that a startup faces,
especially in life sciences, between federal grants at the earliest stages
and  Series  A  venture  investment.  QB3  created  a  micro  seed  fund  to
address the lack of funding for the medical research at the “gathering of
data” stage. Launched in 2009,  Mission Bay Capital raised 11.3 million
USD for their first fund and it is closing now the fourth fund in the amount
of about 13 million  USD. The last fund focuses on medical devices and
does not require  traction of  customers and revenues. Part  of  proceeds
from  the  fund  goes  to  UCSF.  The  Indie  Bio,  “the  worlds’  leading  life
sciences accelerator”, unlocks the technology in just four months through
a very  intense program,  by  providing the wet  lab and partnering with
leading universities and companies. The accelerator focuses on the proof
of principle, sets milestones and lets the company carry out the parallel
experiments to maximize success.
6.3.  Angel investors and Angel Investor groups
An angel  investor  is  an  individual,  who  has  an  accreditation  as  an
investor,  and  who  provides  his/her  own  capital  for  a  business startup,
usually  in  exchange  for convertible  debt or ownership  equity.   “Angel
investments  bear  extremely  high  risks  and  are  usually  subject
to dilution from future investment rounds.  As such, they require  a very
high return  on  the  investment.  Because  a  large  percentage  of  angel
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investments  are  completely  lost,  when  early  stage  companies  fail,
professional angel investors seek investments that have the potential to
return at least ten or more times their original investment, within 5 years,
through  a  defined exit  strategy,  such  as  plans  for  an initial  public
offering or  an acquisition.  “85 Current  investment  climate  dictates  that
angels  might  do  better  setting  their  sights  even  higher,  looking  for
companies that will have at least the potential to provide a 20x-30x return
over a five- to seven-year holding period.86 While the investor's need for
high rates of return on any given investment can make angel financing an
expensive  source  of  funds,  cheaper  sources  of  capital,  such
as bank financing, are usually not available for most early-stage ventures.
With this high return expectations, no wonder that it is not easy to gain
access to “angel’s” money. Standard angel investment is 25,000 USD.87 In
case of angel networks, the founder may raise up to 100,000 USD in one
go.
Besides individual angel investors there are angel investor groups in
the Bay Area, like Sand Hill  Angels of Stanford and The Berkeley Angel
Network  (BAN)  that  share  research  and  pool  their investment  capital.
These networks are the ideal starting point for the unexperienced angel
investor to start investment practices, by observing peers in order to get
the  necessary  experience  that  will  allow  him/her  to  continue
independently  if  s/he  so  wishes88.  Networks  also  allow to  diversify  the
portfolio without the necessity to invest big amounts in a single venture. 
Networks do have different rules of operations. For example Sand Hill
Angels do the collective investments and also bear the collective risks.
The BAN, created in 2011, allows individual investors to make a choice
and commit without a need of collective consent. Compared to some of
the other 16 angel investing groups in the Bay Area, the BAN is on the
informal side, with all members being volunteers. The only criteria to be a
the BAN angel is that one meets the SEC requirements for becoming an
accredited investor, and that one has a UC Berkeley affiliation of some
kind.
63
The groups not only provide startups with seed funding to pursue their
ventures, but also serve as a mentoring and coaching space for the first-
time  entrepreneurs.  Again,  the  level  of  involvement  depends  on  each
participating investor and the group. Fred Drinkwater, an angel investor
with  the  BAN,  said  that  although  angel  investing  takes  a  significant
amount of time and has a very high risk factor — 1 in 10 deals turn out
successful — there is a culture in the Silicon Valley of giving back to the
next generation of  entrepreneurs through mentoring and coaching. For
angel investors, it’s not so much about the money as it is about sharing a
lifetime’s worth of experience with up and coming companies.89
There  are  no  strict  criteria  that  define  whether  or  not  the  angel
investment  will  be  granted  to  the  founders.  However,  one  of  the  top
criteria mentioned by angels is the potential of the founder. This criterion
goes before the technology, prototype, finished product and even before
evaluation of the market profile and size. “They want to know, is there
something sustainable about the solution, the team, and the proposition,
so that as the market and competitive landscape evolve, is the company
the one that is left standing?” says Catherine Chiu, co-president of the
BAN.90
As  it  was  mentioned  above,  angels  are  not  always  risk  takers.
According to David Onek, the BAN tends not to be the lead investor. It
rather  prefers  companies  in  which  someone  has  already  invested
(meaning  that  the  due  diligence  has  been  already  done  and  trust
conferred by another party). In return to the investment, investors ask for
equity  that  may come in  the  form of  SAFE  notes.  The BAN equally  is
looking for some traction, for the company to have already either revenue
or users that are, in fact, the main challenges of the early stage company.
6.4.  Venture Capital Firms
One would expect that VC firms would close the gap between research
and the market. However, the deep tech has a relatively unappealing risk-
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return  profile  compared  with  software  investments.  Moreover,  the
financial interests of investors who participate in the innovation process
are often not in alignment with the social goals of scientist-entrepreneurs.
The venture capital financing is the exception, not the norm, among deep
tech startups. And historically, only a tiny percentage (fewer than 1%) of
U.S. companies have raised capital from the VCs. 
The  VCs,  despite  their  name,  are  quite  conservative.  They  invest
primarily into  a  handful  of familiar  sectors.  They tend to  invest  locally,
they tend to invest only in large markets that are, at least, $1B in size and
they are susceptible to group thinking. “Because VCs are inherently risk
averse, despite the fact that they invest in risky new businesses, they feel
more comfortable in a group where the majority invest in the same sector,
in companies implementing familiar, proven business models.”91
The critics of the VCs say that “The venture capital firms increasingly
look for investment that is not too long-term, not too expensive, and does
not involve too much technology or market risk. “Venture investing shifted
away from funding  transformational  companies  and  toward  companies
that  solved  incremental  problems  or  even  fake  problems.… VCs  have
ceased to be the funder of  the future,  and instead became funders of
features, widgets, irrelevances.”92
Today, according to the National  Venture Capital  Association,  the
largest  venture capital  investors  are pension funds (37% of  investors),
corporations  (23%),  foundations  and  endowments  (16%),  families  and
institutions (12%) and others (12%).93 These are the general numbers of
the typical VC firm: 4,000 proposals are reviewed yearly, 400 startups get
a 30 minutes phone call to discuss a project, 100 are invited for a one-
hour meeting, 20 get funded and about 15 Silicon Valley startups provide
95% of all returns in the Silicon Valley.94 The VCs expect high return in the
short time span. In early 2000, it was not uncommon for a company to
reach an IPO in a year and a half.95 Now, the exit is expected in between
5-7 years, but not more than 10.
“The reason there aren't more Googles is not that investors encourage
innovative startups to sell out, but that they won't even fund them”, says
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Paul Graham, cofounder of Y Combinator, the leading SV accelerator. “The
most surprising thing I've learned is how conservative they (VCs) are. VC
firms present an image of boldly encouraging innovation. Only a handful
actually do, and even they are more conservative in reality than you'd
guess from visiting their web sites. He continues: “I used to think of VCs
as practical: bold but unscrupulous. On closer acquaintance they turn out
to be more like bureaucrats. They're more upstanding than I used to think
(the  good  ones,  at  least),  but  less  bold.  Maybe  the  VC  industry  has
changed. Maybe they used to be bolder. “96
In  effect,  venture capitalists  focus on the middle part  of  the classic
industry S-curve. They avoid both the early stages, when technologies are
uncertain  and market  needs are unknown,  and the later  stages,  when
competitive shakeouts and consolidations are inevitable and growth rates
slow dramatically. “Picking the wrong industry or betting on a technology
risk in an unproven market segment is something VCs avoid.” Exceptions
to  this  rule  tend  to  involve  “concept”  stocks,  those  that  hold  great
promise  but  that  take  an  extremely  long  time  to  succeed.  Genetic
engineering companies illustrate this point. In that industry, the venture
capitalist’s challenge is to identify entrepreneurs who can advance a key
technology to a certain stage—FDA approval, for example—at which point
the company can be taken public or sold to a major corporation.” 
Final Remarks
A collaboration between university, government and industry (a “triple
helix”  model) 97 creates  the  unique  innovation  ecosystem  (or
entrepreneurial ecosystem as referred in some literature) that leads to the
positive  impacts  on  innovation  and  results  in  economic  growth  and
regional  development.98  In  this  model,  university  is  “generating  new
institutional and social formats for the production, transfer and application
of knowledge”99 . In the US,  the universities and industry, up to recently
relatively  separate  and  distinct  institutional  spheres,  are  starting  to
assume tasks that were formerly largely the province of the other.100 Their
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collaboration and interdependence form a foundation of current US model
that facilitates the transfer of research to market.101 
How  can  one  stimulate  the  recognition  of  the  potential  of  the
technology and make a push forward to the commercialization? The Bay
Area answer to it is by a combination of support mechanisms102 that
reinforce  and  complement each  other,  when  implemented
simultaneously.  The  research  by  industry  and  university-related
institutes working on joint research projects, centers for science-industry
collaboration,  incubators  and  accelerators,  new  programs  to  support
startups, including awareness building, networking and mentoring events.
All  of  that  is  complemented  by  assistance  of  the  technology  transfer
offices of the universities, clear IP transfer rules and the mobility schemes
for  researchers  between universities,  government  and industry.  Finally,
funding provided in forms of grants, small business vouchers, angels and
VC money. 
1. Commercialization of Already Available Technologies 
So many new technologies are already created in the laboratories but
remain unexploited.  To create a database of the patents, publish it and
wait for the industry to express the interest has proved to be insufficient.
“Push marketing does not work – creation of patent databases, by the TTO
is not effective”.103 Targeted work on analysis, clustering of patents and
offer  preparation  is  needed.   An  example  is  a  multipatent  portfolio
approach adopted by the National Laboratories in the US, where patents
from the  several  laboratories  are  analyzed  and  clustered  by  the  tech
experts,  in  order  to  build  critical  mass  before  being  presented  to  the
market as a package. University of  California recently launched similar
initiative to map, bundle,  evaluate and revive all  of  university’s  IP and
patents, in order to better commercialize them and better serve industry
interest and needs.104 
Besides,  clear  intellectual  property  transfer  rules,  information  and
hands on assistance in disclosure and filing the patent and its subsequent
licensing help to identify, record, patent and license technologies created
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in  the  universities.  The  support  to  the  scientist  willing  to  become the
entrepreneur  could  help  technology  transfer  to  market.   Assistance  in
incorporation of a new company, advice on legal and financial aspects of
running the company could  help  the creation  of  small  businesses that
constitute the backbone of the US and EU economies.
2. Grants  and  fellowships  support  the  advancement  of  deep
tech technology into a product
An  access  to  targeted  Lab-to-Market  fellowship  programs  is
necessary  to  advance  the  research  in  the  early  stage  deep  tech
technologies.  What makes such programs different  from the traditional
grant schemes is that the possibility of technology transfer to the market
is the key objective and not the research results per se. The example of
the Cyclotron Road program, funded by the DOE Advanced Manufacturing
Office and the California Energy Commission demonsrates advantages in
bringing the researchers from their laboratories to the specifically created
collaborative environment with the very clear mission to advance a
technology  into  the  commercial  product,  so  all  efforts  during  the  two
years program are devoted in achieving this goal. Besides access to the
scientific facilities, fellows receive one-to-one mentorship, access to the
network  and  training  in  business  strategy,  product  development,
personnel  management,  and  many  other  skills  that  are  essential  to
entrepreneurship. Giving the researchers the opportunity to keep their IP
provide additional incentive to participate in such a program. 
3. Access to Shared User Facilities
In the US, the national shared user facilities are open not only to
university  students  and  federal  researchers  but  also  to  startups and
anyone interested in testing and experimenting with the new technology.
Access is provided free of charge to experiment and test new technologies
and  the  advice  of  the  residing  researchers  is  offered.  Even  that  the
primary  focus  is  the  facilitation  of  the  non-proprietary  research,  that
purpose is the publication and not scaling up the businesses. Still, small
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companies  can benefit  from the facilities  and later  use  the  developed
technology for their business purposes.  Joint ownership with university
commercial  forbearance  contract  that  is  at  the  pilot  stage  at  the  UC
Berkeley  allows  startups  to  “rent”  place  in  a  university  laboratory  of
choice  while  keeping  the  IP  rights.  The  laboratory  benefits  from  the
additional  funding,  while  startups  have  the  lab  where  to  develop  the
technology they need. 
4. Defining the Market for the New Technology
Following  success  of  NSF  program,  multiple  federal  agencies  have
successfully adopted a curriculum and one of them (National Institute of
Health) made the attendance of the i-CORPS program a prerequisite for
receiving a federal grant (SBIR). The program’s objective is “to cultivate a
pipeline  of  university-based  researchers  who  can  turn  ideas  into
successful commercial products”. This program helps teams to define and
test the product/market fit of their technology by conducting interviews
with their customers. It pushes the scientists and entrepreneurs to leave
the laboratories and face “the real world” to see if there is a market for
their products. Besides, the program reaches the professors and train
them  in  the  lean  launchpad  approach.  The  professors  in  turn
disseminate this  information  to  their  future  students,  thus
increasing the outreach  of the program.105 
Bringing startups and MBA students together benefit both of them
shows  the  Cleantech2Market  program  developed  by  Haas  Business
School. Startup receive up to 1000 hours of free marketing research and
the  students  get  hands-on  experience  of  the  market.  The  key  of  this
program is a connection between startup, in the possession of the new
technology, and MBA students, willing to apply their business skills to a
real case scenario. That is a win-win for both parties involved. Students
get the experience and credits for the course (and some are employed by
the startup they were working with)  and startup receives analysis of the
future markets where technology can be applied.
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5. Interdisciplinary Research and Dual Degrees
It is more and more common that the technological advances are
happening on the edge of the disciplines. The breakthrough gene editing
technology, CRISPR, was discovered by a biochemist and a microbiologist.
Nanotechnology  is  being  applied  both  in  physics  and  medicine.  Thus,
bringing scientists from different fields closer, facilitating the exchange of
scientific challenges and ideas on how to overcome them, could foster
innovation  and  research.  Interdisciplinarity  becomes  a  key  word  to
describe  the emerging  innovation  model  and universities  and research
centers play a crucial role in it. 
In  order  to  foster  the  innovation  and  technology  advancements,
there is no need to create fixed costly structures. Fluid organizations with
the clear objective and limited time frame (max. 5 years) can offer an
inexpensive and dynamic solutions. The pop-up institutes, with a set date
of termination, allow researchers to be brought together for working on a
problem,  without  removing  them  from  their  laboratories.  The  created
synergies allow to advance the selected field of research from the basic to
applied  science  that  can  be  further  advanced  in  the  next  stages  of
technology development.
Equally,  the  dual  university  degrees  that  combine  chemistry,
engineering or life sciences with entrepreneurship allow the emergence of
the  scientists  with  entrepreneurial  skills.  These  scientists,  with  the
expertise  in  “science”  or  “engineering  but  also  having  business,
leadership and communication skills are better equipped to identify the
commercialization  opportunity  and  to  pursue  the  path  to  the
commercialization. 
6. The Importance of University-Industry Relations
Industry is looking for the first hand access to the new technologies
and new talents. The university-industry collaboration helps industry to
carry out research outside the fixed operational constrains of the running
business.  University  in  turn  receives  industry’s  funding  and,  more
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importantly,  is  able to orient their research in the direction of the real
needs of the industry and markets. Different levels of engagement from
the funding of the whole institute to the limited task specific collaboration,
allow to match the expectation of both parties.  
7. Industry Internal Innovative Practices
Besides traditional R&D departments in the big companies, industry is
searching for alternative ways to innovate. The big companies experiment
with  the  application  of  startup  methodology  to  innovation  inside  the
companies.  By  placing  innovation  teams  outside  the  organization,  the
companies try to create burden free fluid cells, where ideas can be quickly
transformed to the prototype products and tested outside the companies’
traditional  business  processes.  The  creation  of  incubation  or
manufacturing  experimentation  spaces  on  the  margins  of  the  big
companies and inviting the external companies to join these labs, allows
industry  to  follow  the  latest  research  trends  and  invest  in  the  most
promising technologies at the early stage. By creating innovation spaces
or  incubators  inside  the  company,  the  corporations  try  to  keep  the
talented people within the company and also profit from their creations. 
8. Research/Industry Exchange programs 
Exchange  between  industry,  academia  and  government  may  take
many forms – exchanges between scientists and entrepreneurs working
on a common project in the labs, flexible short-term projects, coaching
and mentoring. It allows for a circulation of best practices and ideas. It
unlocks  staff potential  by forcing them to  adopt  different  cultures  and
environments  that enhance the vision and perspective on the process.
The industry members come to the University  to explore technological
challenge  outside  their  organization.  Faculty  members  engage  in  the
entrepreneurial  activities  either  as  mentors,  consultants,  or,  in  some
cases, even as co-founders of startups. 
71
9. The  Dense  Innovation  Ecosystem  With  a  Mix  of  Support
Mechanisms
Bay  area  has  dense  and  strongly  interlinked  innovation  ecosystem
where  industry  and  researchers  work  hand  in  hand  in  driving  the
technologies  to  market.  The  examples  of  Stanford  with  technological
companies spread in proximity to the campus and a Sand Hill Road with
the  venture  capital  firms;  UC  Berkeley,  with  the  Skydeck  accelerator
outside campus and National Lawrence Berkeley Laboratory up the hill,
UCSF  in  Mission  Bay  with  the  biotech  cluster  in  South  San  Francisco,
ensure  that  industry,  finance,  and  science  participate  in  constant
interaction.  The  mix  of  support  mechanisms is  available  to  the
researcher, founder and entrepreneur from which he/she could pick the
best suited ones. These support mechanisms are not limited to funding.
Network,  mentoring,  access  to  the  laboratories,  advice  on  IP,  are  all
crucial  for  facilitation  of  research  to  market  transfer.  The  tendency
observed in the Bay Area is that with time the (successful) accelerators
grow in size (number of startups accepted) and also create their venture
funds  to  secure  the  early  stage  investments  for  the  most  promising
companies. As no one yet unlocked the “secret source” of Silicon Valley
and there is no single “recipe for success” for the few unicorns originated
in the Valley, the tendency is to diversify the investments and not limit
the access to the support programs to a specific country and institution or
technological vertical. In the selection of projects, the emphasize is made
on  the  diversity of  the  project  selection  committee:  having  different
backgrounds and skills represented provides different perspectives on the
future of the technology and the company. “If  everyone agrees on the
project, it is most likely not worth pursuing”106. 
I  describe  in  my report  some initiatives  that  I  observed in  the  US,
California during 2018-2019, during my stay at the University of California,
in Berkeley, as an EU fellow. Some of them are in the pilot stage so their
impact still  needs to be assessed.  To sum up, what measures can
facilitate  a  transfer  of  research  results  to  the  market?  First,
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clear technology transfer rules and assistance to the patenting
and  the  licensing  process  both  to  the  university  and  Federal
laboratories  and  the  industry.   Second,  the  enhancement  of
technology  innovation  networks  by  fostering  (Federal  and
university)  laboratory  engagement  with  the  industry. Third,
exchange of talented people with complementary skills between
government,  academia, and industry.  And the last but not the
least, the access to finance. 
Many initiatives, similar to those described, are already implemented in
different  parts  of  Europe.  Ireland  cooperates  with  the  US  on  sending
teams  to  participate  in  the  I-Corps  program.  SchoolLab,  a  French
accelerator, applies Lean Startup methodology of Stanford to advise their
startups.  European Universities offer entrepreneurial courses, incubator’s
space and mentoring for those who wants to launch their company. Is the
knowledge diffusion and quality and density of the lab-to-market program
the  same across  the  EU countries  and  regions?  Probably  not.  Are  the
current initiatives enough? What more can be done in order to boost the
European  innovation  ecosystem?  What  US  initiatives  and  programs
described in this report shall be promoted in Europe and if any, at which
level?  Is  it  up  to  the  EU,  national  or  regional  authorities  or  individual
universities and businesses to promote and administer such initiatives? I
hope with this report to open the discussion on these topics. 
73
1 https://ec.europa.eu/research/evaluations/index_en.cfm?pg=hlg
2 The White House briefing of 2014 stated that “Federal Government spends more than $130 billion on research and 
development (R&D) each year, conducted primarily at universities and Federal laboratories….some research discoveries 
show immediate potential for commercial products and services, and the President is committed to accelerating these 
promising technologies from the laboratory to the marketplace, based on closer collaboration with industry.”
https://obamawhitehouse.archives.gov/blog/2014/03/14/lab-market-accelerating-research-breakthroughs-and-economic-
growth
3 In his management agenda of 2018, Donald Trump pointed out five strategies for the Federal agencies: 
 To identify regulatory impediments and administrative improvements in Federal technology transfer policies
and practices; 
 To increase engagement with private sector technology development experts and investors; 
 To build a more entrepreneurial R&D workforce; 
 To support innovative tools and services for technology transfer; and 
 To  improve  understanding  of  global  science  and  technology  trends  and  benchmarks.
https://www.whitehouse.gov/wp-content/uploads/2018/04/ThePresidentsManagementAgenda.pdf
4 The valley of death –is a common term in the startup world, referring to the difficulty of covering the negative cash flow in
the early stages of a startup, before their new product or service is bringing in revenue from real customers.
5 The new technology, the invention can be born both during the so called basic or applied research process, while the
latter is by definition closer to the market.  In biotech and life sciences  the term used is translational research, the process
of applying knowledge from basic biology and clinical trials to techniques and tools that address critical medical needs.
Unlike applied sciences, translational research is specifically designed to improve health outcomes. It uses an integrated
team of experts who are focused on translating useful information from laboratories to doctors’ offices and hospitals, so
called “bench to bedside” bridge.
6 The company CELLFE developed the cell delivery technology that had been discovered by error in the laboratory of the 
Georgia University. Interview with CEO Alla Zamarayeva, 18 October 2018
7 Garry Duffy, PI of Duffy Lab at the School of Medicine at the National University of Ireland Galway (NUIG) mentions that
several unexpected incremental innovations had been created during his Horizon 2020 project implementation. Interview 7
February, 2019.
8 Prepared by Stanford Technology Transfer Office
9 For detailed criteria of patentability, one may consult: https://en.m.wikipedia.org/wiki/Patentability
10 In Europe there are no provisional patents. However, the cost of filing European patent is significantly lower than in the 
US, and the cost is the main consideration for filing the provisional patent in the US.
11 https://science.energy.gov/lp/technology-transfer/
12 https://en.wikipedia.org/wiki/Bayh%E2%80%93Dole_Act
13 In Europe, each country has its own rules regarding ownership of the invention. For example, in Sweden, it is an inventor 
who owns the IP rights, while in Denmark it is the university (interesting topic for the future research:  how different 
ownership models affect the countries’ invention capacity).
14 www.ipira.berkeley.edu/sites/default/files/shared/docs/Startup_Guide.pdf
15 www.ipira.berkeley.edu/sites/default/files/shared/docs/Startup_Guide.pdf
16 Industries most impacted by Deep Tech breakthroughs include: life sciences, aerospace, clean energy, robotics, agtech, 
and computing. https://www.quora.com/How-would-you-define-deep-tech
17 The America Invents Act of 2011 switched U.S. right to the patent from the previous "first-to-invent" system to a "first-
inventor-to-file" system for patent applications filed on or after 16 March 2013.
18 The interview with CellFe CEO Alla Zamarayeva on 11 December
19 Interview with  Deepak Dugar, Founder, Director , Visolis, 15 January 2019
20 HorizonEU programme makes a distinction between two types of funding: one a “pathfounder” focus on technology
development and another one is “accelerator” focus on the growth and scale up of the company. 
21 Interview with  Ioana Aardei, Entrepreneurship Program Manager at the California Institute for Quantitative Biosciences
22 There are several forms of licensing arrangements that can be used by a start-up company especially the one that does 
not yet have the financing. Letter agreement, the simplest form of the licensing arrangement allows “to delay” the entering
into force of the licensing agreement providing 3-12 months for negotiations and legalization of the deal. It helps the 
company to incorporate and seek the financing if it has not been already done. Option agreement, is another type of 
arrangement giving the opportunity to take an option on the obtaining the license during the period between 1-3 years in 
return to fixed annual fee. This arrangement gives the opportunity for a start to advance further its business model, and to 
confirm that the selected technology would ultimately fit within the product line.  License agreement is the final option, 
giving the rights to the company to sell commercial products. The duration of the agreement is normally the same as the 
life of the patent. For this type of agreement, the startup has to funds to be able to conclude it. In certain cases, University 
accepts “equity’ in a company as a partial consideration for technology transfer.
23 At the University of California according to the current policy, 35% of royalties go to inventor.  
24 Interview with Mike Cohen, Director of TTO UC Berkeley, 20 September 2018 “IPIRA (Intellectual Property and Research
Alliance) is very open to the possibility of licensing technology to campus startups, and educating faculty about Bayh-Dole
regulations could foster a deeper understanding of IPIRA’s role. We also note that faculty should, and often do, designate a
startup company representative to negotiate a license, in order to avoid a financial conflict of interest.” 
25 This assertion is based on the interviews. The formal communication from the TTO of UCBerkeley states that “nearly all 
IP licenses to startup companies are exclusive to provide an inventive to invest in high-risk research and development and 
to reward entrepreneurs for their commitment to the commercialization process” (from Entrepreneurs’ startup guide of 
IPIRA) 
26 Entrepreneurship at Berkeley, report of 20 July 2018 of the VC for research
27 Depending on the staffing, workload and governance, some TTOs limit  themselves to the legal technology transfer
assistance (as the office of the MIT, for example, that due to the high number of invention disclosures does not have the
capacity to go beyond its traditional role). Others extend their role to support the faculty in startups’ creation (in the case
of UCSF).
As for the governance structure, some TTOs are part of a university and report to campus leadership while others
(UCLA) are created in a form of a non-profit entity (the UCLA Technology Development Corporation) and are independent
from the university.
At MIT, TTO is allowed to take 15% off the top of the royalty revenue to help pay for its operations. At UCSF, funding
comes primarily through the Dean of the School of Medicine, and unlike Stanford or MIT, there is no connection (e.g.,
percentage) between revenue generated by Innovation Ventures and the operating budget. As an independent entity, the
UCLA Technology Development Corporation endeavors to adopt a business mindset and operate on the cycle of business
as opposed to an academic one. 
The review process is also different. For the review process at MIT, UC Berkeley and UCSF, the staff meets regularly
(weekly at MIT) to decide “go” or “no go” on  the files for provisional applications for all invention disclosures received that
week. At Stanford, the licensing agents enjoy complete autonomy in the evaluation process  and have the authority to veto
the patent application. (Entrepreneurship at Berkeley, report of 20 July 2018 of the VC for research) 
28 Interview with Elsie Quaite-Randall, Lab's Chief Technology Transfer Officer Lawrence Berkeley National Laboratory, 1 
November 2018
29 Article “The Changing Relationship Between Academia and Entrepreneurship”, Published on April 21, 2019, Chief 
Innovation Officer, Christine Gulbranson,  https://www.linkedin.com/pulse/changing-relationship-between-academia-
christine-gulbranson-phd-mba/
30 https://research.csiro.au/oznome/tools/readiness-level-metrics/
31 
https://arpa-e.energy.gov/?q=site-page/tech-market-t2m
32 https://500.co/blockchain-company-vc-fundable/
33 http://fortune.com/2018/06/20/renata-quintini-lux-capital/
34 Visit  to  Sandler  Neurosciences Center  6 December,  Neuroscape laboratory,  meeting and lab visit  with  Peter  Wais,
Faculty, Assistant Professor - Neurology
35 The Silicon Valley Edge: A Habitat for Innovation and Entrepreneurship (Stanford Business Books) , Stanford  university 
press, 2000, 424 p, P.189
36 https://arpa-e.energy.gov/?q=arpa-e-site-page/arpa-e-history
37 https://vcresearch.berkeley.edu/sites/default/files/2018-08/Entrepreneurship_at_Berkeley.pdf
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